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ABSTRACT
Atp10c/ATP10C is a putative aminophospholipid translocase or “flippase” that
encodes for a type 4 P-type ATPase. Based on previous research, we hypothesize that
Atp10c/ATP10C due to its flippase nature plays a role in diet-induced obesity and type 2
diabetes as Atp10c heterozygous mice display this phenotype.
For purposes of this dissertation, Atp10c/ATP10C was characterized both
generally and biologically to gleam information about its molecular weight, cellular
location and possible biological roles and/or functions. Multiple experiments, both in
vitro and in vivo, were performed in order to accomplish these characterizations and are
discussed at length.
Essential results from this dissertation work include the validation of ATP10C’s
expected molecular weight (~165 kD), the localization of ATP10C to the plasma
membrane, its possible co-localization with GLUT4, and the high expression of Atp10c in
key tissues (skeletal muscle and adipose tissue) of two mice models, one a model of dietinduced obesity mice and another a genetic model (ob/ob).
To identify molecular and cellular targets of ATP10C, Atp10c expression was
altered in vitro in C2C12 and L6-G4myc skeletal muscle myotubes. Functional outcomes
of GLUT4 translocation and glucose uptake assays were performed resulting in the
significant alteration of normal GLUT4 regulation and a significant decrease in glucose
uptake. Additionally, when the expression of Atp10c was altered both experimentally and
genetically, significant up-regulation of native and activated mitogen-activated protein
kinases, p38, and ERK1/2 were observed. These results demonstrate that Atp10cv

silencing does affect these main mitogen-activated protein kinase proteins and in turn,
glucose metabolism via both insulin-independent and insulin-dependent manners.
Taken together, all these results presented in this dissertation indicate that
Atp10c/ATP10C has an important role in the regulation of glucose metabolism, at least in
part via the mitogen-activated protein kinase pathway, and as such, plays a significant
role in the development of insulin resistance and type 2 diabetes.
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CHAPTER I
INTRODUCTION
Disease Epidemics
The incidence of type 2 diabetes mellitus (T2D) and diet-induced obesity (DIO) is
increasing rapidly and reaching epidemic proportions throughout the world populations.
Although the cause of T2D remains unclear, it is known that insulin resistance (IR) is
closely related to the development of the disease. IR is also linked with other metabolic
syndromes and it is considered to be a major contributing factor to diseases including
hypertension, atherosclerosis and coronary heart failure. IR is characterized by a failure
of the hormone, insulin, to result in efficient glucose disposal, and particularly produce its
normal increase in glucose transport in peripheral tissues namely skeletal muscle and
adipose tissue. Defective glucose uptake in skeletal muscle and adipose tissues plays a
major role in causing IR and glucose intolerance symptoms associated with T2D. Under
normal conditions for humans and most other mammals, skeletal muscle accounts for
approximately 80% of the glucose uptake impacting overall glucose homeostasis; adipose
tissue accounts for only 5-20 % of glucose disposal. The rate-limiting step in glucose
uptake is glucose transport mediated by the facilitative glucose transporter 4 (GLUT4),
which is mainly expressed in skeletal muscle, cardiac muscle, and adipose tissues. In
response to insulin, GLUT4 translocates from the cytoplasm to the cell membrane and
mediates the transport of glucose into the cell [1, 2, 3, 4]. Defects in any part of the
insulin signaling pathway have been shown to contribute in the pathogenesis of IR. How
impaired glucose uptake and defective insulin signaling in skeletal muscle contributes to
whole body IR remains unanswered. As such, defining the molecular nature of these
1

processes has become an important research and therapeutic goal for the prevention and
treatment of IR and T2D.

Genetics, Environment or Factors of Both
It is clear that the molecular etiology of IR involves multiple genetic and
environmental mechanisms contributing to the final disease state [5]. Atp10c, a type 4 Ptype ATPase, is a putative aminophospholipid transporter (APLT) identified as a strong
candidate for DIO and T2D. Previous data from our laboratory suggest that the
heterozygous deletion, along with maternal inheritance of the chromosomal region on
mouse chromosome 7 containing the single gene Atp10c, resulting in the manifestation of
DIO, T2D and non-alcoholic fatty liver disease (NAFLD) [2]. Although the exact
mechanism and biological role of ATPases, like Atp10c, are still poorly understood,
extensive research in yeast shows that these ATPases are important in protein trafficking
primarily in endocytic and exocytic pathways [6, 7]. The hypothesis of this dissertation
is that there is an association between the type 4 ATPase, Atp10c, and cell signaling and
intracellular protein trafficking with regards to those pathways involved in glucose
metabolism. To investigate this believed association, the specific muscle cell lines,
murine C2C12 and rat L6 overexpressing GLUT4-myc (L6-G4myc), were used as in
vitro models of myogenesis and non-insulin and insulin stimulated cell signaling.
Western immunoblotting in conjunction with immunofluorescence analysis and real-time
polymerase chain reaction (qPCR) experimental techniques were used to monitor changes
in gene and protein expression after Atp10c/ATP10C-silencing using RNAi technology.
Alterations in gene and protein expression were also measured before and after insulin
2

stimulation. These experiments helped identify key molecular and cellular targets of
Atp10c in glucose metabolic pathways. Additionally, functional assays of glucose uptake
and GLUT4 translocation were conducted in order to elucidate Atp10c/ATP10C’s role in
pathways involved in these processes namely the phosphatidylinositol-3-kinase (PI3K)
and the mitogen-activated protein kinase (MAPK) pathways as well as the
endocytosis/exocytosis of GLUT4. Basic characterization of Atp10c/ATP10C involved
the use of HEK293T cell line and an Atp10c/ATP10C-overexpression plasmid.
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CHAPTER II
LITERATURE REVIEW
Insulin Resistance (IR) and Type 2 Diabetes (T2D)
In 2010, the global prevalence of diabetes was 284 million, or 6.4% of the world
population. Projections for the year 2030 estimate that the prevalence will be almost
double (439 million) comprising roughly 7.7% of the world population [8]. Diabetes,
whether type 1 or 2, is a disease in which the body does not produce or properly use
insulin, a hormone needed to convert sugar, starches, and other foods into energy. The
most common form, T2D, is characterized by IR primarily of skeletal muscle and adipose
tissue in combination with decreased to no pancreatic β-cell activity. Skeletal muscle is
responsible for the majority of insulin-stimulated glucose clearance in the body and
insulin’s effects are achieved via the stimulation of glucose uptake into targeted tissues.
In T2D, there is a failure to increase glucose disposal into peripheral tissues in response
to insulin, leading to chronically elevated levels of glucose (hyperglycemia) in the
circulation followed by a compensatory rise in insulin (hyperinsulinemia). The elevated
glucose and insulin levels, in turn exacerbate IR, contributing significantly to the
pathogenesis of the disease [9].
IR is often associated with metabolic syndrome, an assemblage of symptoms
including obesity, glucose intolerance, and dyslipidemia. Metabolic syndrome too has
reached epidemic proportions in the Western world [10]. Problems arise more often as
metabolic syndromes are undiagnosed and allowed to progress. As a result of this failure
to diagnose, patients may experience persistent hyperinsulinemia, resulting in detectable
apoptosis of pancreatic β-cells and full T2D [11].
4

Another often referenced co-morbidity of T2D is DIO. The two are so often
associated with each other that the term “diabesity” has been coined to describe the
concurrence of both diseases. Obesity is defined as excessive adiposity in relation to lean
body mass, which may involve both altered body fat distribution and enlarged adipose
depot size. DIO is the result of an imbalance in energy homeostasis, whereby excessive
food intake is not balanced by energy expenditure [12]. Declared a major health problem
by the World Health Organization as early as 1985, DIO is a growing epidemic.
Although excess fat storage is not a contagious disease in a literal sense, the epidemic
metaphor is used to capture the rapidly rising levels in many nations [13]. DIO, like
T2D, is a complex, multifactorial syndrome that is influenced by genetic as well as nongenetic factors. The etiology of obesity involves complex interactions among excessive
caloric dietary habits, sedentary lifestyles, and genetic background [12]. Despite the
obvious assumption that the recent rise in obesity has predominantly environmental and
nutritional causes, around 40% of obesity can be attributed to hereditary factors [14].
Weight-gaining predispositions (i.e., the differences between individuals) are considered
by geneticists to be highly heritable with as much as 70-80% of weight variation
attributed to genetic factors; the only trait with higher heritability than weight-gain
predisposition in humans is height. Accordingly, scientists and public health officials
recognize that there must be a complex array of factors at play in weight gain and DIO
[12]. The characterization of such factors in the population, which could be inherited or
acquired during life, would be a huge step in scientific research and healthcare. The need
for personalizing and improving healthcare is one important factor that has driven the
search for new predictive biomarkers. Biomarkers are used to identify the risk, presence,
5

and/or susceptibility to disease, and also to guide diagnostic and therapeutic interventions
and to individualize the treatment of distinct conditions within clinically similar
populations, including DIO and T2D [12].
T2D has several more co-morbidities that are equally as harmful as obesity, if
not more so. Adult patients with T2D, especially those with poor glycemic control,
additionally experience hypertension, dyslipidemia, and non-alcoholic fatty liver disease
(NAFLD), as well as having an increased risk for vascular complications. Moreover,
these disorders may be present before the diagnosis of T2D and, like T2D, are associated
with excessive weight. Although data in children and adolescents with T2D is limited,
results suggest that they too are at increased risk for the same vascular complications
similar to those seen in adults [15].
Hypertension is defined by experts as systolic and/or diastolic blood pressure
greater than 130/80 mmHg as measured on three or more separate occasions. Treatment
for hypertension calls for changes in lifestyle (dietary and physical) as well as
pharmaceutical intervention. Such treatment also involves the diagnosis and treatment of
any and all underlying causes of hypertension like T2D and/or its related co-morbidities
[15].
Another common co-morbidity of T2D, dyslipidemia, often requires specialized
treatment. Dyslipidemia is defined as a lipoprotein disorder that promotes the
development of atherosclerosis and includes increased low-density lipoprotein cholesterol
(LDL-C), decreased high-density lipoprotein cholesterol (HDL-C), and increased
triglycerides. In patients with T2D, IR, relative insulin deficiency, and obesity are
associated with hypertriglyceridemia, low serum HDL-C, and, occasionally, high serum
6

LDL-C concentration. Although dyslipidemia is not as common in children as in adults
with T2D, a substantial proportion of young patients with T2D have abnormal serum
lipids. Like hypertension treatment, non-pharmacologic therapy (diet, exercise, improved
glycemic control, and weight reduction) is recommended as the first intervention for
dyslipidemia. If the goals of reduction in all symptoms are not met, then medications are
required for alteration of lipid levels [15].
DIO and T2D are associated with a clinical spectrum of liver abnormalities
collectively known as NAFLD. NAFLD is the most common cause of liver disease in
children, and is particularly common in children with T2D. Abnormalities include
hepatic steatosis (increased liver fat without inflammation) and nonalcoholic
steatohepatitis or NASH (increased liver fat with inflammation). NASH may lead to
fibrosis, cirrhosis, and liver failure if left untreated. However, for patients with simple
steatosis or mild steatohepatitis, the likelihood and risk factors for progression to more
severe liver disease are unknown. Following the common theme of treatment, nonpharmacologic therapy (diet, exercise, improved glycemic control, and weight reduction)
is initially used to manage NAFLD. Pharmacologic invention is reserved for patients
over 10 years of age, who fail non-pharmacologic invention, have elevated LDL-C (>160
mg/dL, 4.14 mmol/L), and/or other cardiovascular risk factors [15].
Based on the staggering numbers presented, there is a desperate call for new
research to examine the relationship between T2D and its co-morbidities. To understand
the underlying causes and to clarify unknown players in metabolic pathways related to
these disorders is an important goal in T2D research. Problems arise in the study of such
complex disorders as searching for genes related to IR and T2D presents with major
7

issues, mainly genetic and environmental components. The genetic component of these
diseases is based on multiple, single genes that act together with one or more genes which
may be exposed to specific environmental factors. As early as the 1990s, geneticists
were able to argue that human obesity genotypes are complex polygenic systems with
networks of gene-gene and gene-environment interactions. As such, the growing number
of obesity-related or obesity-causing genes does not bode well for the single gene
hypothesis [12], nor does a single-gene hypothesis work for complex metabolic disorders
like IR and T2D. Furthermore, if research focuses specifically on a single gene and its
effect on IR and T2D while failing to examine and manage for other known as well as
unknown genes and environmental factors involved, results of experimental and clinical
studies become difficult to interpret. Since these factors are difficult to control in human
subjects, polygenic diseases can be more easily studied in cell culture models.
Information gleamed from these studies conducted in this dissertation as well as
numerous research performed by other laboratories can then be translated into animal
models and ultimately extrapolated into human homologs and phenotypes.

Cell Culture Models to Study IR and T2D
In vitro cell culture models have been used extensively in research to investigate
numerous disease states. Using in vitro cell culture models allows the manipulation of
target genes, which can aid investigators in recognizing biological functions without
having to deal with the complexities involving whole animals or human subjects. As
skeletal muscle is the target tissue of interest for glucose clearance and as such a
desirable object of study in regards to IR and T2D, cell culture models used must exhibit
8

similar characteristics and behaviors of the tissue under investigation. These include the
murine skeletal muscle cell line C2C12 and the altered rat L6 overexpressing a GLUT4myc tag (L6-G4myc).
Mouse C2C12 cells are well-characterized murine skeletal muscle cell lines [16]
that have been frequently utilized. Several investigators have reported that insulin
stimulated the glucose uptake in C2C12 under differentiated conditions, thus simulating
the in vivo status [17, 18]. Unlike C2C12 myoblasts which express only the non-insulin
sensitive GLUT1, fully differentiated C2C12 myotubes express GLUT4 and glucose
uptake can be activated by insulin [19]. However, others reported that the cell line lacks
sensitivity to insulin [20]. This discrepancy can be explained by the instability of C2C12
cells [18]. Some advantages of these cells include their ability to undergo phenotypic
differentiation and cell fusion [16] easily and show relatively good differentiation in
terms of sarcomere development compared with other established cell lines, such as the
rat L6 [21]. Still, C2C12 myotubes have not been widely utilized to study insulinstimulated glucose uptake because they express relatively low levels of GLUT4 [22]
when compared to GLUT4 expression from L6 cell lines and primary skeletal muscle
cultures from mice.
As such, a cell line of rat skeletal muscle, L6-G4myc, has been developed and
widely used. L6 G4mycs offer the ability to undergo phenotypic differentiation and cell
fusion, as well as afford the opportunity to compare GLUT4 translocation with glucose
uptake in intact cell preparations, as required to assess possible changes in GLUT4
activity [9]. Skeletal muscle cell lines like rat L6 cells have been used to study insulininduced glucose transport systems. However, problems can arise with these myoblast
9

cells as they need to be differentiated by replacing the calf serum with horse serum or by
dexamethasone treatment [18]. Some researcher forego this step of differentiation and
use myoblasts alone [9, 22, 23], but this protocol is controversial as myoblasts do not
accurately represent mature myotubes and/or adult skeletal muscle. The same literature
states that the GLUT4-myc tag is responsible for both basal and acute insulin-stimulated
glucose uptake in L6-G4myc cells [9]. Thankfully, this cell line can still be used to study
GLUT4 translocation as the L6-G4myc muscle cell line has detectable myc-GLUT4
translocation upon insulin stimulation [1].
Understanding the pros and cons of both cell lines and the limitations of in vitro
research is crucial for investigating biological functions without having to deal with the
complexities involving animal models. For the purpose of our research, our laboratory
has chosen to utilize both cells lines in their undifferentiated and differentiated forms
(myoblasts and myotubes) to study Atp10c/ATP10C, a putative phospholipid translocase
that may be a major player in glucose and lipid metabolism.

P-type ATPases and Atp10c/ATP10C
Biological membranes exist of amphipathic lipid molecules that self-assemble
into bilayers in an aqueous environment due to their intrinsic property of a hydrophilic
head group and a lipophilic tail. Each membrane is composed of hundreds of lipids
systematically distributed. In eukaryotic cells, the main lipids of cellular membranes
phosphatidylcholine (PC), phosphatidylserine (PS), phosphatidylethanolamine (PE) and
phosphatidylinositol (PI) all of which are glycerophospholipids. Other major classes of
lipids are sphingomyelin and glycerosphingolipids, which are phosphosphingolipids.
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Cholesterol, a steroid of fat, is also an essential structural component of mammalian cell
membranes and is required to establish proper membrane permeability and fluidity.
Lipids are asymmetrically arranged between the two leaflets of the plasma membrane,
and this was first thought to be a static characteristic of membranes. However, it is now
clear that the lipid topology results from a continuous bi-directional movement of lipids
between the two leaflets or “flip-flop” in which specific membrane proteins have an
essential role [24]. A phospholipid molecule can diffuse rapidly throughout one leaflet,
but faces a substantial barrier to the “flipping” of its polar head group through the
hydrophobic interior of the membrane to the other leaflet. Consequently, the two leaflets
of a membrane can be completely different in phospholipid composition [25].
Asymmetry of the plasma membrane is made possible by lipid-translocation machinery
that hydrolyses ATP to flip aminophospholipids against a concentration gradient i.e. the
APLT [24, 26].
While lipids can freely diffuse in the lateral plane of the membrane, transverse,
or flip-flop movement of lipids in the plasma membrane is very slow (from hours to
days) [25, 27]. For the creation and maintenance of the asymmetrical distribution of
phospholipids, eukaryotic cells have evolved an elaborate set of proteins, which must be
actively maintained. These proteins are divided into three classes – “floppases”,
“flippases”, and “scramblases”. “Scramblases”, facilitate a lipid- specific transverse
movement of phospholipids in either direction. “Floppases” also known as the ATPbinding cassette (ABC) transporters maintain transbilayer distribution of phospholipids
by translocating specific phospholipid species from the inner to the outer leaflet of the
bilayer (flop) at the expense of ATP [7, 27]. The third class of proteins that facilitate
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transverse transport of phospholipids across biological membranes are the APLT or
“flippases” [27].
The first flippase activity was described in 1984 in human erythrocytes [7, 28].
Subsequent work by several laboratories defined the biochemical properties of this family
of transporters and the identification of a new branch in the phylogenetic tree of the Ptype ATPase superfamily -- the type 4 subfamily [7]. The P-type ATPase superfamily is
an evolutionary conserved, large family of proteins members of which are widely
expressed in both prokaryotes and eukaryotes, including bacteria, yeast, parasites,
nematodes, insects, plants, and animals [6]. P-type ATPases in multicellular organisms
show distinct tissue distribution and specific roles in development. In addition, P-type
ATPases reside in multiple, often very specific, cellular compartments, from the plasma
membrane to specialized secretory vesicles suggesting high spatial regulation of P-type
ATPase function. As such, dysfunctional P-type ATPases can potentially influence the
spatial and/or temporal availability of phospholipids, and thus the distribution and
activity of proteins [29].
As integral transmembrane proteins, P-type ATPases are important in the
generation of cation gradients which make these proteins indispensable in the regulation
of cell volume, excitability of nerve cells, muscle contraction, intracellular pH, acid
secretion in the stomach, uptake of substrates, and signaling pathways [6]. The core of
all P-type ATPases contains a conserved stretch of seven amino acids with the P-type
signature sequence FDKTGT [L, I, V, M] [T, I, S] [6]. This motif includes an aspartic
acid residue, which is essential in the reaction cycle of the protein. The mechanism via
which substrates are pumped is based on the E1E2 model, in which ATP-mediated
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phosphorylation, substrate binding, and subsequent dephosphorylation of the invariant
aspartic acid are coupled to a conformational change of the transporter. The
phosphotransfer reaction drives the transport cycle of these proteins, hence the name Ptype ATPase [6].
The type 4 P-type ATPases form a separate group based on sequence divergence
(approximately six subclasses) [28, 29] and their assumed role involves the translocation
of phospholipid molecules across biological membranes rather than cations [6, 28]. The
members of this subfamily have 10 -12 predicted transmembrane domains with an NH2and COOH-termini protruding into the cytoplasm, and a large intracellular loop harboring
P-type ATPase-specific sequences and an ATP-binding site [6, 24, 27]. Type 4 P-type
ATPases differ from the cation-transporting P-type ATPases in that they lack negatively
charged residues involved in ion transport [24]. Over 100 members of the type 4 P-type
ATPases subfamily have been identified, all of which are exclusively found in eukaryotic
organisms, including approximately a dozen human isoforms [28]. The type 4 P-type
ATPases are proposed to catalyze the flippase activity that restricts PS and PE to the
cytosolic leaflet of the plasma membrane. Slow flop of phospholipids without head
group specificity, combined with rapid flip of PS and PE, is thought to establish the
observed membrane asymmetry [29].
In mammalian plasma membranes, the aminophospholipids, PS and PE are
stationed to the inner leaflet of the membrane bilayer, while PC and sphingolipids are
found in the outer leaflet. APLTs translocate PS and/or PE from one leaflet of the
membrane bilayer to the other, and seem to be responsible for concentrating PS and PE
on the cytosolic leaflet of biological membranes [30]. The highly organized and
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maintained distribution of phospholipids is crucial for many physiological processes.
Some of these processes include signal transduction, cell morphology, cell movement,
activity of membrane proteins, and vesicle biogenesis. Conversely, the ability for
phospholipid randomization is essential in initiating processes like phagocytosis, platelet
activation, and apoptosis. Therefore, to continue the asymmetric flux of the phospholipid
bilayer, proteins that translocate the phospholipids are necessary.
Much of the present knowledge on the cellular function of type 4 P-type ATPases
has been gained from studies of Saccharomyces cerevisiae as the yeast genome has five
type 4 ATPases. The founding member of this subfamily is the yeast drs2 gene (an
ortholog of mouse Atp10c). This particular gene has been shown to participate in
ribosomal assembly, the formation of Golgi-coated vesicles, and in maintenance of
bilayer asymmetry. These activities are indispensable for intracellular membrane and
protein trafficking, fluid-phase and receptor-mediated endocytosis, processes that require
lipid flipping to initiate budding and the fusion of membrane vesicles from or with other
membranes [6, 26, 28, 30]. Studies in yeast strains defective in single or multiple type 4
ATPases have accumulated data implicating these proteins in the biogenesis of transport
vesicles and thus the establishment of cellular polarity [6, 30]. Furthermore, these
proteins act in distinct, yet overlapping pathways [6].
In humans, 14 type 4 P-type ATPase genes have been identified, all with mouse
orthologs [7]. The study of type 4 P-type ATPase mutants has linked many of these
enzymes to the maintenance of membrane structure, vesicle trafficking, and amphipath
transport. At least two have been associated with human diseases [28]. Atp10c, located
on mouse chromosome 7, is putative APLT and a novel type 4 P-type ATPase as it
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contains three conserved motifs consistent with this family of ATPases. Heterozygous
Atp10c mice represent a genetic, diet-induced polygenic model of T2D, in association
with DIO. These heterozygous mice are hyperinsulinemic, have IR and have an altered
insulin-stimulated response in peripheral tissues, namely skeletal muscle and adipose
tissues. The phenotype of Atp10c heterozygous mice further strengthens their biological
role in intracellular signaling and protein trafficking and suggests that metabolic
pathways of glucose metabolism can be used to delineate this function.
Although a substantial amount of indirect evidence has implicated a number of
proteins as “flippases,” positive identification awaits their purification, reconstitution, and
demonstration of transport activity [28]. Moreover, the molecular mechanisms by which
these proteins act are not fully understood due to the difficulties that arise when
developing reliable assays to study intramembranous transport [7]. The cellular
consequences of defects in type 4 P-type ATPases vary from vesicle formation
deficiencies to membrane structure/stability defects. These defects have secondary
consequences, making it difficult to pinpoint the biochemical functions of the type 4 Ptype ATPase family [27]. Studying these proteins is a challenge, but successful research
will provide fundamental insight with regard to membrane dynamics and protein
trafficking. In addition, it will clarify the molecular mechanisms which underlie severe
human diseases [6] like T2D and its related disorders.
For now, only one inherited disorder has been directly linked to mutations in a
type 4 P-type ATPase gene -- ATP8B1 [6]. Byler disease or PFIC1 is a rare autosomal
recessive disorder first described in the Amish population. The disease primarily
manifests as a chronic intrahepatic cholestasis which progresses to severe, end-stage liver
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disease before puberty. A less severe clinical phenotype associated with mutations in
ATP8B1 is benign recurrent intrahepatic cholestasis [6]. Five studies by four
independent groups suggest that ATP8B1 plays a critical role in maintaining stability of
the plasma membrane of polarized epithelial cells [27]. How exactly ATP8B1 stabilizes
the plasma membrane is currently unknown, but could involve phospholipid translocation
as well as recruitment of proteins involved in cytoskeleton dynamics. As observed in
human erythrocytes, loss of phospholipid asymmetry also leads to morphological
aberrations and is accompanied by dis-attachment of cytoskeletal elements from the
membrane [27].
Numerous studies have been conducted on APLTs and lipid membranes. Results
of these studies suggest their role or possible roles in insulin signaling, further solidifying
the importance of type 4 P-type ATPases in cell biology and health and disease [7].
Studies using a similar protein from the same family as Atp10c also showed promising
results. Researchers discovered that of the 15 inbred mouse strains available for research
purposes, only the C57BL/6J strain contained a premature stop codon in ATP10D,
resulting in a non-functional protein. It is interesting to note that C57BL/6J mice are
predisposed to develop obesity, hyperglycemia, hyperinsulinemia, and hypertension
when fed a high-fat diet [7]. Moreover, this protein was also proposed to be a candidate
for the modulation of the HDL-C levels. Since ATP10C and ATP10D belong to the same
class of type 4 P-type ATPases, they may be involved in similar pathways. Thus, both
may play a role in trafficking routes implicated in glucose and lipid metabolism [30, 31].
Additional type 4 P-type ATPase genes have been implicated in association with
multiple diseases. The Atp8a2 gene was reported to be frequently deleted in tumorigenic
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malignancies; however, no relation between defective phospholipid translocase activity
and tumorigenesis has been demonstrated at this time. Recently, Atp11c has been
mapped to a chromosomal region (Xq27) associated with X-linked inherited disorders
including hypoparathyroidism, albinism, deafness, and thoracoabdominal syndrome. If
and how this ATPase contributes to these disease phenotypes however remains to be
demonstrated.
The focus of our research, Atp10c/ATP10C, has been studied by others in
relation to several neurological diseases. ATP10C/ATP10C has been linked to the
neurological disorders including Angelman syndrome (AS) and autism [32, 33]. AS
sometimes referred to as “happy puppet” syndrome is a neurological disorder
characterized by ataxia, mental retardation, hyperactivity, subtle dysmorphic facial
features, epilepsy, and an apparently happy, social disposition, and is a disorder in which
genetic imprinting plays a role. This syndrome has been associated with mutations and/or
deletions in a maternally-derived, chromosomal region which includes the ATP10C and
UBE3A genes. The UBE3A gene encodes the ubiquitin-protein ligase E3A, an enzyme
involved in the ubiquitination of proteins. Surprisingly, ATP10C expression is nearly
absent in patients with AS. One obesity phenotype of AS has been described in threequarters of patients suggesting causation from a lack of ATP10C activity. For the
remaining quarter of AS patients, no obesity phenotype has been described. Rationale for
those patients is that mutations occur only in the UBE3A gene and that the ATP10C gene
is intact [33]. It is highly likely that the syndrome relates to the UBE3A gene rather than
to ATP10C as transgenic mice with the maternal UBE3A gene knocked out,
phenotypically resembled human patients, and most importantly are not obese.
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Autism is a developmental disorder characterized by three areas of abnormality - impaired social interaction, communication, and restricted stereotyped pattern of
interest or behavior. Impairment in all three areas is generally observed before 3 years of
age and disrupted growth of the brain is implicated in the etiology of autism. Numerous
studies have indicated a robust role of genetic factors in the development of both autism
and AS, while no susceptibility gene has been elucidated [32]. Further confounding
matters is that some individuals with autism have a maternal duplication of the AS
region. However, paternal inheritance of the same duplication has no effect. Also,
conflicting studies on the involvement of ATP10C in autism have arisen. Two notable
studies by Nurmi et al. 2002 [34] and Kim et al. 2002 [35] did not observe a significant
association between ATP10C /ATP10C and autism, while one by Kato et al [32] did.
Rationale for ATP10C /ATP10C involvement comes as recycling of membrane from
neuronal synapses plays a critical role in synaptic vesicle production. In addition, the
recycling or polarized delivery to specific sites on the plasma membrane is essential for
proper function of neurons and may contribute to long-term potentiation.
Atp10c /ATP10C has been implicated in several metabolic abnormalities, and as
such, is an ideal candidate for DIO and T2D. As stated earlier, mice inheriting a maternal
deletion of Atp10c are considered a model of DIO and T2D as these mice develop
hyperinsulinemia, IR, increased adiposity, impaired glucose tolerance, and NAFLD
compared to mice inheriting the same deletion paternally [7, 12, 28, 31, 36]. Research by
Dhar et al. [2] showed that after a high fat diet for 12 weeks, higher insulin levels were
measured in Atp10c heterozygous mice. These mice also had a hyperglycemic response
in an insulin tolerance test and showed impaired glucose uptake in adipose tissue and the
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soleus muscle. Interestingly, these mice showed altered expression of a set of genes
involved in insulin-stimulated glucose uptake in peripheral tissues, including Glut4,
which is required for glucose uptake into myocytes and adipocytes. Further validation
can be observed in a mouse model of AS. Researchers using human subjects also
identified a subset of AS patients with the additional phenotype of increased body mass
index (BMI) suggesting that ATP10C/ATP10C may play an important role in obesity of
multiple etiologies, in mice and humans, respectively.
Additionally, other groups of investigators other than us have been looking at the
biological role of ATP10C gene or its cognate protein, ATP10C, in metabolism. Several
independent reports suggest that the epigenetic background of individuals may depend on
a number of genetic and environmental factors acquired over ones’ life or inherited from
the parents. In a recent study by Milagro et al [12], researchers looked at whether or not
changes in dietary patterns including hypocaloric diets and weight loss were able to alter
the methylation profile of different genes. Results from this study revealed that some
metabolically relevant genes were hypomethylated before any intervention. For ATP10C,
significant differences between low and high responders were observed before the
intervention. Diet-induced changes in fat mass and BMI were also observed confirming
that it could be a reliable marker of successful response to the hypocaloric diet [12].
These results show that changes in dietary patterns, including hypocaloric diets and
weight loss, are able to alter the methylation profile of different genes one of them being
ATP10C, again validating its possible role in DIO and T2D. These results and the
extensive research described above lead to the need to investigate the pathways involved
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in glucose metabolism to find roles for ATPases like Atp10c /ATP10C in these metabolic
disorders.

Glucose Metabolism Pathways and Insulin Resistance
Glucose transporters (GLUT) are known to play pivotal roles in energy
metabolism. Many different eukaryotic GLUT isoforms have been identified and well
characterized. They possess 12 transmembrane helical segments with the N- and Ctermini and a large central loop exposed to the cytoplasm. GLUTs have distinct antigenic
C-terminal regions, and are subject to different metabolic and developmental regulations.
GLUT1 is located primarily in the plasma membrane in most tissues, whereas GLUT4 is
found predominantly in intracellular membranes in insulin-sensitive tissues such as
adipose tissue and skeletal muscles [37, 38, 39]. Glucose transport activity is affected by
changes in the intrinsic activity, intracellular trafficking, and stability of the GLUTs. A
number of mechanisms are involved in regulating the expression of GLUTs. GLUT
expression can be regulated by the transporter itself, by other GLUTs, or other
transcription factors. For instance, GLUT4 may interact with appropriate signal
transducers which in turn regulate the level of functional transcription factors [37]. In the
absence of stimulation, GLUT4 is almost completely excluded from the plasma
membrane. The addition of insulin causes GLUT4 to shift from its intracellular location
to the plasma membrane [40]. Several observations indicate that GLUT4 has a crucial
role in whole body glucose homeostasis. Insulin stimulated glucose transport is an
important rate-limiting step for glucose metabolism in both skeletal muscle and adipose
tissue, and is severely disrupted in T2D. Disruption of GLUT4 expression in mice results
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in IR, while an overexpression of GLUT4 showed improved diabetes in a genetic mouse
model of T2D (db/db) [40]. Because skeletal muscle is the principal target tissue for
glucose clearance and is the main tissue involved in insulin-stimulated glucose uptake,
the GLUT4 protein content of skeletal muscle is of the utmost importance [39].
A key event in insulin-stimulated glucose transport is the translocation of the
facilitative GLUT4 to the plasma membrane [4]. In mammals, GLUT4 is of particular
relevance to insulin action because its expression is confined to insulin-sensitive cell
types such as skeletal muscle, adipose tissue, and cardiac muscle [41]. In response to the
activity of insulin, GLUT4-containing storage vesicles (GSVs) rapidly translocate
towards the plasma membrane. Myotubes also express GLUT1, which can undergo
translocation by insulin, but is more often responsible for basal or non-insulin stimulated
glucose uptake. Responsible for majority of insulin-stimulated glucose uptake into
peripheral tissues is GLUT4, a 12-transmembrane domain protein that mediates transport
of glucose in the direction of the glucose gradient [40]. GLUT1 contributes only a small
extent to the stimulated glucose transport as described by Bazuine et al [41]. Treatment
with the GLUT4 inhibitor rottlerin reduced insulin-stimulated glucose transport to nearbasal levels of transport. The concentration of GLUT4 in the plasma membrane
determines the rate of glucose metabolism in adipose and muscle cells, which in turn
contributes to whole-body glucose homeostasis [4]. In normal cells, GLUT4 is
distributed among the plasma membrane and various intracellular membrane
compartments. Insulin stimulation significantly increases the exocytic rate of GSVs
while inhibiting GLUT4 endocytosis [42, 43, 44]. While GLUT1 may be found both
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inside and outside the cell, GLUT4 vesicles have rarely, if ever, been found at the plasma
membrane of un-stimulated muscle or fat cells [40].
Maintenance of lipid asymmetry has been implicated in membrane bending and
the biogenesis of endocytic and secretory vesicles. An excess of lipid on one side causes
the lipid bilayer to bend, and this process then contributes to the formation of transport
vesicles. Although APLT activity may enhance vesicle formation, this activity alone is
not enough to drive this process [26, 27]. Several investigators have shown that ATPases
participating in distinct trafficking pathways and that these proteins are important for the
biogenesis of exocytic and endocytic transport vesicles. In fact, membrane bending and
the generation of a lipid imbalance across the bilayer is a prerequisite for vesicle budding.
Phospholipids can rapidly cross the bilayer in both directions and the assembly of a
protein coat sufficient to deform the bilayer into a bud is not a problem when adopting a
transbilayer lipid arrangement permissive for vesicle formation. However, in the plasma
membrane, the free ‘flip-flop’ of phospholipids across the bilayer is constrained and
therefore a problem for vesicle budding without assistance of ATP-driven flippases [24,
43]. Direct participation of ATP-driven flippases in vesicle formation is supported by the
observation that inward translocation of PS and PE by APLT in the plasma membrane of
human erythroleukemia cells stimulates endocytosis. Intriguingly, yeasts lacking type 4
P-type ATPases genes, Dnf1p, Dnf2p and Drs2p display a general defect in endocytosis.
Conversely, overexpression of ABC transporters with outward directed lipid translocase
activity causes a defect in endocytosis. This suggests that lipid translocation is required
to either generate a membrane environment permissive for vesicle formation or perhaps
to help deform the membrane during vesicle budding. Further biochemical analysis of
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these proteins will be required to better assess their role in protein trafficking [29, 30].
Collectively, all these results suggest a functional link between lipid transport and vesicle
formation [24]. Several groups have demonstrated that these proteins participate in
distinct intracellular vesicular trafficking pathways and are important for the biogenesis
of exocytic and endocytic transport vesicles. Importantly, these functions are closely
linked to the flipping of phospholipids or phospholipid analogues [31]. The formation of
GSVs is mandatory for the translocation of GLUT4 and as a result, is necessary
requirements for insulin-stimulated glucose uptake.
Additional evidence that GLUT4 is essential in the maintenance of normal
glucose homeostasis is that mice carrying a muscle-specific deletion of the Glut4 gene
developed severe IR and glucose intolerance. Another study using an adipose-specific
Glut4 knockout mouse model also showed that these mice developed IR and glucose
intolerance [1].
IR is a key feature of T2D. In particular, it has been argued that elevated levels of
glucose (hyperglycemia) and insulin (hyperinsulinemia) are major factors for the
development of IR, but the molecular mechanisms remain obscure [9]. The
compensatory increase in insulin during the insulin resistant state initially offsets
insulin’s reduced ability to stimulate GLUT4 translocation and glucose uptake.
However, both in vivo and in vitro studies demonstrate that the hyperinsulinemic state has
a negative effect on insulin action. Insulin strongly promotes GLUT4 incorporation into
the cell surface, and this translocation appears to fail in IR accompanying T2D [5].
Understanding the regulation of GLUT1 and GLUT4 has proved to be extremely
challenging, principally because it involves several signal-transduction pathways that are
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superimposed on a complex series of vesicle transport processes. The rate of glucose
uptake in skeletal muscle and adipose tissue is limited by the total number of facilitative
glucose transport proteins inserted into the plasma membrane. Acute insulin treatment
activates not only glucose transport activity, but also the translocation of some GLUT1
and all GLUT4 transporters from intracellular sites to the plasma membrane. Multiple
studies show that GLUT transport activity can be modulated, directly or indirectly, by
protein–protein interaction, post-translational modification of the transporter, and/or
changes in cellular environment [38, 41]. Insulin binds to a surface receptor on muscle
and fat cells triggering a cascade of signaling events that culminates in GLUT4
translocation. In the absence of insulin, GLUT4 is largely excluded from the plasma
membrane and is retained within endosomes, the trans-Golgi network, and tubularvesicular compartments. Insulin triggers the redistribution of GLUT4 from intracellular
compartments to the plasma membrane. This action increases the total number of
transporters localized to plasma membrane and thus the maximal rate of glucose transport
into cells. When insulin is removed, GLUT4 is rapidly cleared from the plasma
membrane back into intracellular compartments, where it is recycled for use in
subsequent stimulations [44].
Studies of this process of GLUT4 translocation have been carried out using two
approaches. The first is an “outside–inside” approach that focuses on mapping the
insulin-specific signaling pathway, PI3K, in skeletal muscle and fat cells with the view to
identifying downstream targets that directly control GLUT4 translocation. Conversely,
the second approach is an “inside–outside” one used to map the intracellular transport

24

itinerary of GLUT4 with the aim of identifying insulin-regulated steps [40] which may or
may not be regulated by MAPK.

Phophatidylinositol-3-kinase (PI3K) pathway
Insulin furthermore initiates several signal transduction pathways in the
cytoplasm of the cell [1, 41]. Years of research has shown that insulin activates
downstream signal transduction cascades by binding to its receptor, thus activating it. On
a cellular level, metabolic IR is known to display a reduced strength of signaling via the
PI3K pathway. In almost all cases of IR there is a decline in PI3K activity. Two
complementary mechanisms have emerged as potential explanations for the reduced
strength of the PI3K signaling pathway. The first explanation is that the PI3K activity is
minimized secondary to serine phosphorylation of insulin receptor substrate (IRS)
proteins, specifically IRS-2 in skeletal muscle. A disruption in the balance between the
amounts of the PI3K subunits may also explain the development of IR. PI3K consists of
a regulatory subunit, p85, and a catalytic subunit, p110. As this heterodimer is
responsible for PI3K activity, any increase or decrease in p85 expression could inversely
lead to increased or decreased PI3K activity. In a study following acute overfeeding,
human females displayed reduced whole body insulin sensitivity and showed an increase
in total p85expression in skeletal muscle. This increase in p85 expression was inversely
correlated with PI3K activity [45].
When insulin binds to its receptor, the occupied insulin receptor then undergoes
auto-phosphorylation and phosphorylates IRS [41]. A key component of an insulin
signaling cascade is the activation of PI3K and its downstream kinases such as Akt. Akt
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kinase activity is dependent on its phosphorylation at Thr308 and at Ser473 [46]. Akt is
known to mediate many of the physiological effects of insulin including GLUT4
translocation by phosphorylating downstream substrates [1, 4, 46]. Akt is often regarded
as the most important substrate in the insulin signaling pathway because many
physiological effects of insulin stimulation are mediated by Akt kinase activity. There
are three Akt isoforms, but only the Akt2 isoform has been shown to be necessary for
insulin-stimulated GLUT4 translocation and glucose uptake in skeletal muscle and
adipose tissue. Furthermore, Akt2 knockout mice have impaired muscle and fat glucose
uptake [41]. This trafficking process is in part mediated by AS160, an AKT substrate
that is critically involved in insulin-stimulated regulation of GLUT4 trafficking.
Interestingly, AS160 activation is reduced in patients with T2D [4]. AS160 has also been
shown to associate with GLUT4 containing vesicles. Immunohistochemical analysis of
AS160 indicated that it has a wide intracellular distribution that partially overlaps with
GLUT4 and that it is absent from the plasma membrane. Unlike GLUT4 which is located
in only insulin-sensitive tissues, AS160 has a widespread tissue distribution [47, 48].
Recently, studies using an in vitro fusion assay of intracellular vesicles that contain
GLUT4 with plasma membranes showed that insulin modulates targets in both the vesicle
and the plasma membranes. Therefore, this data supports the notion that there are several
signaling pathways that join different aspects of GLUT4 transport [40]. Consequently it
can be hypothesized that the development of IR induced by chronic exposure to glucose
and insulin is at least not exclusively mediated products of the PI3K pathway alone but
might also involve other signaling pathways [4]. One such pathway is mitogen activated
protein kinase (MAPK) pathway. Therefore, the data from all these studies show the
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importance of the PI3K pathway in glucose metabolism and its exploration alone and in
conjunction with the MAPK pathway warrants further investigation.

Mitogen activated protein kinase (MAPK) pathway
Chronic inflammation and metabolic dysregulation are prominent features of
T2D, cardiovascular disease, and several other disease states. The pathological stress
underlying these conditions trigger persistent fluctuations through multiple intracellular
signaling pathways that amplify the diseased state. As master regulators of gene
expression and metabolism, MAPK proteins have been shown to couple cellular stress
with an adaptive or maladaptive response in skeletal muscle.
Numerous studies have concluded that insulin stimulates glucose uptake via the
rapid recruitment of GLUT4 to the surface of skeletal muscle and adipose tissue.
However, many studies have shown that the extent of GLUT4 recruitment to the cell
surface in response to an acute insulin challenge is less than the extent of the increase in
glucose uptake [48, 49]. This discrepancy between glucose uptake and GLUT4
translocation may be reconciled if the intrinsic activity of GLUT4 were also elevated by
insulin. Taken together, these observations suggest that GLUT4 at the cell surface may
require activation by some critical mechanism before it can transport glucose to its
maximum capacity [48, 49, 50]. It has been suggested by various researchers that insulin
increases glucose uptake by first increasing GLUT4 translocation and then further
activating the additional transporters in a separate pathway from the PI3K pathway. It is
hypothesized that after translocation toward the plasma membrane, there is a secondary,
MAPK-dependent step, leading to enhancement of insulin induced glucose uptake [41].
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Recent work has demonstrated that the MAPK protein, p38, is necessary for
insulin-stimulated glucose uptake. Inhibition of p38 can prevent insulin-stimulated
glucose uptake, but not GLUT4 translocation, suggesting that p38 may regulate this yet
to be discovered activation step. Thus, in acute situations, p38 is beneficial to GLUT4mediated glucose uptake. However, when chronically exposed to insulin, p38 also
contributes to the development of IR, as inhibition of p38 improved GLUT4 protein
levels and insulin-stimulated glucose uptake. The detrimental effects of p38 activation
are further supported by the observation that constitutive activation of the p38 pathway
decreased GLUT4 messenger RNA and protein levels as well as insulin-stimulated
glucose uptake [9, 50].
These signaling modules consist of a three-tiered kinase core where a MAPKKK
activates a MAPKK that activates a MAPK [51, 52, 53]. The MAPK family of proteins
is composed of distinct signaling modules in skeletal muscle including extracellular
signal regulated kinases (ERK) 1 and 2, p38, and c-Jun NH2-terminal kinases (JNK).
These MAPK branches are stimulated by cytokines, growth factors, and cellular stress
[54]. MAPK proteins are 60-70% identical to each other, yet differ in their activation
loop sequences and sizes. Downstream substrates of MAPK include mitogen-activated
protein-kinase-activated protein kinases and transcription factors, the phosphorylation of
which, either directly or indirectly, regulate gene expression at several points, including
transcription, nuclear export, and mRNA stability and translation [55]. Much scientific
evidence suggests that unrestrained signaling perpetuates IR and protein catabolism. As
such, MAPK represents exciting targets for pharmacological interventions aimed at
preventing or improving T2D and muscle wasting [54].
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The ERK pathway was the first MAPK pathway to be identified. The ERK
pathway is activated by numerous stimuli, including growth factors, cytokines, viral
infection, and carcinogens [53, 54, 55]. ERK1 (p44) and ERK2 (p42) are co-expressed in
virtually all tissues but with a remarkably variable relative abundance [56]. ERK1 and
ERK2 MAPKs are activated by phosphorylation on threonine and tyrosine residues by
the dual specificity kinase MEK1, which induces their translocation into the nucleus
where they activate or repress a variety of transcription factors [57]. The functional
consequence of ERK pathway activation includes cell-cycle regulation, proliferation, and
cell survival [55]. Studies have demonstrated that in pancreatic β-cells, glucose is known
to activate ERK1/2 and that glucose-induced ERK1/2 activity remains in the cytoplasm
and participates in the regulation of insulin secretion in MIN6 cells [57].
The JNK family of enzymes is inflammation and stress-activated MAPKs
involved in the regulation of cell proliferation, survival, and apoptosis, but the underlying
mechanisms of actions in these processes are unclear [52]. Three mammalian isoforms,
JNK1, JNK2, and JNK3, are encoded by distinct genes that are highly homologous, but
differ in tissue expression. JNK1 and 2 are ubiquitously expressed, while JNK3 is more
restricted to the central nervous system, heart, and testes [54].
As a separate signaling component of the MAPK network, p38 MAPK consists of
four isoforms (p38 α, p38 β, p38 Δ, and p38 ). Tissue-selective expression is observed,
with p38  found predominantly in skeletal muscle, p38 Δ in the testes, pancreas, and
small intestine. In contrast, p38 α and β are more ubiquitously expressed [49, 54, 55].
Significant amino acid sequence homology is observed among the 4 isoforms, with 6075% overall sequence homology. Dually activated by phosphorylation on tyrosine and
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threonine residues, p38 is capable of regulating many cellular processes including cell
morphology, differentiation, apoptosis, as well as expression of numerous target genes.
In one study, research showed that p38 is necessary for the full differentiation of
preadipocytes into adipocytes [56]. Interestingly, studies also show that p38 contributes
to insulin-mediated glucose uptake in adipocytes [10, 50]. These results support the tenet
that p38 MAPK may be a regulator of glucose uptake and is altered in states of IR [9].
For this reason, the role of the MAPK pathway, specifically p38 involvement, in
regulating skeletal muscle differentiation has been studied extensively, but the results
have been mixed [58].
The molecular mechanisms involved in the induction of myoblast differentiation
and fusion are complex and to date, remain unclear. A coordinate induction of musclespecific gene products occurs along with morphological changes of differentiation.
Members of the MyoD family of muscle-specific transcription factors (MyoD, myogenin,
Myf-5, MRF4) are involved in these processes, and their ectopic expression in a variety of
non-muscle cells can promote myogenesis [16]. Studies revealed that modulating the p38
pathway with chemical or upstream kinase activators or inhibitors regulated the activity
of the promoters of muscle-specific marker genes such as myogenin and MyoD [52].
MyoD triggers differentiation of myoblasts by activating the expression of the fourth and
last muscle regulating factor implicated in myogenesis: myogenin [58]. Investigators
showed that in vitro blocking the p38 pathway seriously perturbed cytoskeletal
organization during the terminal stages of myogenesis [52]. Researchers conducting this
study also observed data that suggested an interaction between the p38 and the PI3K
pathway. Controversy arises as the differentiation of an in vitro cell line of mouse
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skeletal muscle, C2C12 cells was not accompanied by any activation or inhibition of
ERK2. Moreover, inhibitor PD098059, which prevents activation of the MAPK
pathway, had no apparent effect on myotube formation or on the expression of
differentiation markers such as myogenin or MyoD. Instead, SB203580, a specific
inhibitor of p38 blocked myotube formation and the expression of muscle-specific
proteins [57, 58]. The literature on the response of ERK1/2 and JNK activity to
differentiation in C2C12 myoblasts is mixed, from decreased to unchanged to increased
[58] so the roles of these proteins remains yet to be solved. Data from all the studies
discussed above serve as evidence that the MAPK pathway is an important pathway in
many vital biological processes and as such, its role in glucose metabolism warrants
further investigation.

Gene/Protein Modification Techniques
RNAi interference (RNAi)
With the advent of synthetic silencing RNA (siRNA) technology, RNA
interference (RNAi)-based gene silencing in cultured cells has been extremely valuable in
dissecting elements crucial for the cell signaling pathways. RNAi is a post-transcriptional
gene silencing technique that was first coined in 1998 to describe the observation that
double-stranded RNA could be used to block gene expression. siRNA is a class of double
stranded RNA molecules generally 19 to 25 nucleotides in length, which act to interfere
with the expression of mRNA. These siRNAs are either generated in vitro by cleavage of
double-stranded RNA using the enzyme Dicer or generated synthetically and introduced
into the cell experimentally. Routinely, commercially available and synthesized siRNA
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is transfected into cells to form a complex with the RNAi-induced silencing complex
(RISC). After the duplex or plasmid unwinds, a single antisense strand guides RISC to
the messenger RNA (mRNA). Binding of the strand at the complementary sequence
results in cleavage of the targeted mRNA, thus the final outcome is targeted silencing of a
particular gene of interest [59]. Due to the endogenous expression of proteins at the time
of transfection and subsequent mRNA silencing, some protein has already been
translated, so complete silencing or knockdown of the protein of interest may not be
possible at this level, but should be greater than 70% at the mRNA level for transfection
to be deemed efficient.
Gene silencing by siRNA in cultured mammalian cells is being used as an
effective way to quickly test if a specific gene is required for a biological function. It is
additionally being used in high throughput screens to determine if there are any genes
within a large set of genes required for a particular function. The use of RNAi is
definitely an important experiment to conduct before more expensive experiments to
generate transgenic mice are undertaken.

Overexpression
Overexpression of a particular cDNA and its product is another effective way to
characterize a gene and to study possible biological function of its cognate protein. The
process of overexpressing a particular gene/protein of interest involves a complicated
procedure of cloning and subcloning. Cloning is the process of moving a gene from the
natural occurring chromosome to an independently replicating vector. During this
process, the DNA is removed from select cells and manipulations of the DNA are carried
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out before the DNA is then put back into cells. Because the bacteria E. coli is so well
characterized, it is usually the cell of choice for manipulating DNA molecules. Once the
appropriate combination of vector and cloned DNA/construct has been made in E. coli,
the construct can be put into other cell types for further experimental use [60]. Often
times after cloning a gene of interest, researchers analyze the gene’s characteristics by
overexpression analysis of the gene of interest into various cell types [61]. For the
purpose of analyzing insulin-stimulated glucose transport, the most commonly selected
cell lines are skeletal muscle and adipose tissue. However, the introduction of DNA or
genes of interest into these insulin-responsive tissues by standard transfection protocols
are very inefficient and time consuming [61, 62]. As such, many times investigators will
use another cell line to perform these overexpression studies. Human embryonic kidney
cells, also known as HEK293 cells, have been grown in tissue culture for many years and
are very widely used as they are relatively easy to grow and transfect readily. An
important variant of this cell line is the HEK293T cell line that contains the SV40 large T
antigen, which allows for replication of transfected plasmids containing the SV40 origin
of replication. This benefit allows for amplification of transfected plasmids and extended
expression of the desired gene products [63, 64].

Research Project Overview
Although there is a consensus on the physiological function of flippases in
intracellular signaling and protein trafficking, their precise biological roles are poorly
understood. The hypothesis of this project is that there is an association between type 4
ATPase mediated phospholipid translocase activities, cell signaling and intracellular
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protein trafficking. Based on the phenotype of Atp10c heterozygous mice, these
processes can be studied in metabolic pathways of glucose metabolism. Since
Atp10c/ATP10C is a novel product and as such, little is known regarding its function, the
purpose of our research is to explore both the PI3K and MAPK pathways measuring
changes in the expression of key proteins when Atp10c/ATP10C expression is altered via
experimental gene and protein modification techniques. RNAi will be used to alter the
expression of Atp10c/ATP10C in vitro and a commercially available plasmid construct
containing ATP10C cDNA coupled with a GFP cDNA will be used in a similar fashion
for this project to characterize Atp10c/ATP10C and hopefully, identify its location within
the cell, thus estimating possible biological functions. The skeletal muscle cell lines,
murine C2C12 and rat L6-G4myc were used as the in vitro systems to investigate the
biological role of Atp10c/ATP10C in PI3K, MAPK, and endocytosis/exocytosis of
GLUT4. Specific experiments and the corresponding results will be discussed in greater
detail throughout the remainder of this dissertation.
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CHAPTER III
EXPERIMENTAL INVESTIGATIONS
General Characterization
Abstract
Atp10c is a putative phospholipid “flippase” that encodes for a type 4 P-type
ATPase. Based on previous research, we hypothesize that ATP10C due to its flippase
nature plays a role in DIO and T2D as Atp10c heterozygous mice display this phenotype.
For our investigation, we characterized Atp10c/ATP10C in order to gleam information
about its biological role and/or function. In order to do this, an ATP10C-GFP plasmid
construct was commercially obtained and transfected into HEK293T cells. Results
showed a band at the expected molecular weight, about 165 kD. Next,
immunolocalization by fluorescence confocal microscopy was employed, and we were
able to show that the ATP10C-GFP fusion protein localized to the plasma membrane of
HEK293T cells; also we see some co-localization of ATP10C with GLUT4 (about 81%).
Finally, the expression of Atp10c in two mice models, one DIO and the other genetic
(ob/ob) was measured. Results from these experiments revealed a high expression in all
the tissues tested. The expression of Atp10c was highest in fat for the ob/ob mice (2.94
fold). For the DIO mice, the expression of Atp10c was higher in the skeletal muscle (3.78
fold). All the results presented strengthen Atp10c’s role in glucose and lipid metabolism.
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Introduction
Due to the staggering numbers of new incidents of DIO and T2D reported each
year, there is a desperate call for new research to examine the relationship between T2D
and its co-morbidities, to understand the underlying causes those diseases, and to clarify
unknown players in metabolic pathways related to T2D and other related disorders.
However, problems arise in the study of such complex disorders as searching for genes
related to IR and T2D presents with major issues, mainly genetic and environmental
components. The genetic component of these diseases is based on multiple, single genes
that act together with one or more genes which may be exposed to specific environmental
factors. As early as the 1990s, geneticists were able to argue that human obesity
genotypes will be complex multigenic systems with networks of gene-gene and geneenvironment interactions. As such, the growing number of obesity-related or obesitycausing genes does not bode well for the single gene hypothesis [12]. Nor does a singlegene hypothesis work for complex metabolic disorders like IR and T2D. Furthermore, if
research focuses specifically on a single gene and its effect on IR and/or T2D while
failing to examine and manage for other known as well as unknown involved genes and
environmental contacts, then results of experimental and clinical studies become difficult
to interpret. Since these factors are difficult to control in human subjects, polygenic
diseases can be more easily studied in cell culture models. HEK293 cells have been
grown in tissue culture for many years and are very widely used as they are relatively
easy to grow and transfect readily. An important variant of this cell line is the HEK293T
cell line that contains the SV40 large T antigen, which allows for replication of
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transfected plasmids containing the SV40 origin of replication. This benefit allows for
amplification of transfected plasmids and extended expression of the desired gene
products [63, 64]. For our investigation, we decided to use this cell culture model,
HEK293T to look at Atp10c/ATP10C, a putative phospholipid translocase or “flippase”,
in order to gleam information about its biological role and/or function in glucose
metabolism. We hypothesize that as a putative flippase, Atp10c/ATP10C should be
localized in or around the plasma membrane. Moreover, we believe that Atp10c/ATP10C
plays a role in DIO and T2D as mice heterozygous for Atp10c/ATP10C display this
phenotype and should be highly expressed in tissues responsible for glucose metabolism.
Materials and Methods
HEK293T, a commercially-available cell line, was purchased from Open
Biosystems (Thermo Fisher Scientific, Waltham, MA). Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 5% heat-inactivated FBS (fetal bovine serum), 100
units/ml penicillin and 100 μg/ml streptomycin, radioimmunoprecipitation assay (RIPA)
buffer, and ABsolute Blue SYBR Green ROX quantitative PCR mix were also from
Thermo Fisher Scientific (Waltham, MA). DMEM with 1% antibiotics and 10% FBS is
furthermore referred to as the complete growth media. The protease inhibitor (pi) cocktail
in dimethyl sulfoxide (DMSO) was obtained from Sigma Aldrich (St. Louis, MO). A
Bicinchoninic Acid Kit (BCA) and an Enhanced Chemiluminescence (ECL) Western
Blotting Detection Kit were purchased from Pierce Biotech Inc. (Rockford, IL) and used
in protein experiments. Primary antibodies, β-tubulin, Calnexin, and Rab5, as well as the
secondary antibody, horseradish peroxidase (HRP)-conjugated anti-rabbit IgG, were
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obtained from Cell Signalling Technology (Danvers, MA). All immunofluorescence
materials (protein blocks [normal rabbit], negative control [normal rabbit] and antibody
diluent) were purchased from BioGenex (San Ramon, CA). Secondary antibody specific
for immunofluorescence application, Alexa Fluor 568 donkey anti-rabbit, as well as
Prolong Gold Anti-fade reagent and wheat-germ-agglutinin (WGA) were purchased from
Invitrogen (Carlsbad, CA). RNeasy Mini Kit and QuantiTect primer assays for Atp10c
were from Qiagen (Valencia, CA). Quantitative PCR primers specific for mouse
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) were designed using the Primer 3
program (http://primer3.sourceforge.net) and were commercially obtained from Operon
(Huntsville, AL). The iScript cDNA synthesis kit was acquired from Bio-Rad
Laboratories (Hercules, CA). The ATP10C-GFP plasmid and TurboFectin along with
anti-DDK monoclonal antibody and peroxidase conjugated affinity purified goat antimouse IgG were purchased from OriGene Technologies, Inc (Rockville, MD). The
GLUT4- expression plasmid was generated and graciously obtained by our lab from Dr.
Jeffrey Pessin (University of Iowa, Iowa City, IA). Glass bottom culture dishes from
MatTek Corporation (Ashland, MA) were also used for immunofluorescence
experiments.

Cell Culture
HEK293T cells were cultured as described elsewhere [62, 63, 64]. Roughly 1.0 x
103cells were seeded in either a 60-mm dish. They were then maintained at 37°C and 5%
CO2 in complete growth media. At the appropriate confluency, cells were harvested for
use in subsequent experiments.
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Mouse Treatment and Sample Collection
DIO mice as well as ob/ob and their control littermates were purchased from the Jackson
Laboratory (Bar Harbor, ME). For DIO mice, male C57BL/6J mice were fed a high-fat
diet (60% kcal % from fat) (Research Diets, New Brunswick, NJ) or regular chow diet
for 20 weeks before being euthanized at 26 weeks of age. Male ob/ob and their controls
were fed a chow diet for 8 weeks before being euthanized at 14 weeks of age. The mouse
studies were approved by the Institutional Animal Care and Use Committee (IACUC) at
the University of Tennessee.

RNA, cDNA synthesis, and qPCR
The following procedures were performed as described elsewhere [2, 65, 66]. Cells were
washed with ice cold 1X HBBS and total RNAs were isolated using RNeasy Mini RNA
kit (Qiagen), according to the manufacturer’s instructions. Single-stranded cDNA was
synthesized using the iScript cDNA synthesis kit (Bio-Rad), and amplified using genespecific primers by qPCR with mouse Gapdh as the housekeeping gene. All mRNA
expressions were achieved by qPCR using ABsolute SYBR Green ROX quantitative
PCR mix on the Strategene Mx3005P with MxPro analysis software under the following
PCR conditions: 1 cycle of 50°C for 15 min and 95°C for 2 min, followed by 40 cycles of
95°C for 25 s, 52°C for 25 s and 72°C for 1 min. The relative abundance of target gene
expression was calculated using the 2-ΔΔCT and standard curve method, with ΔΔCT
being the difference between CT of the target gene normalized with respect to the Gapdh
CT [67].
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Transfection of ATP10C plasmids
TurboFectin is a transfection reagent optimized for nucleic acid delivery into eukaryotic
cells. Its proprietary formulation of lipid/histone blend is supplied in 80% alcohol [68].
TurboFectin has been tested and shown to be very effective in the delivery of cDNA
clones for gene overexpression like the ATP10C-GFP and GLUT4-RFP plasmids. As
TurboFectin was used as the transfection reagent, standard protocol provided by the
manufacturer was followed. Briefly, two days before transfection, HEK293T cells were
plated at a density of 1.0 x 103 cells/dish in complete growth medium and grown to
obtain 50-70% confluency. Cells were then incubated overnight and transfection
proceeded the following day. To form the transfection complex of reagent and DNA, 100
uL of serum free medium plus the appropriate amount of TurboFectin (2-6 uL per 1 ug
DNA based on manufacturer’s instructions) were added to a tube. After mixing
completely by gentle pipetting, this solution was incubated at RT for 5 min before the
addition of the respective plasmid DNA (1-3 ug per well) to the TurboFectin-containing
media prepared above. The two solutions were gently mixed and allowed to incubate at
RT for 30 min. During this incubation period, the cells were removed from the incubator
and the spent medium replaced with 2 mL of fresh complete medium per dish. Upon
complex formation, the solution was added to the seeded cells drop-wise and distributed
evenly throughout the dish. Cells were cultured for 24 and 48 hours before either
harvesting for RNA and/or protein, or undergoing immunofluorescence analysis.
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Preparation of cellular extracts, immunoblotting, and immunofluorescence
Total cell lysates were isolated using RIPA buffer according to standard methods [65, 66,
69].

Briefly, cells were washed twice with 1X HBBS and lysed in RIPA buffer

containing pi at 4°C for 30 min. Lysates were centrifuged at 16,000g for 10 min at 4°C.
Protein estimation was performed using the BCA kit (Pierce Biotech) with an internal
standard, according to the manufacturer’s instructions. Immunoblot analysis was carried
out according to standard procedures [65, 66, 69]. Equal concentrations (25−100 μgs) of
proteins were resolved on 10% SDS-PAGE, using 5X Laemmli sample buffer containing
Tris-HCL (375 mM, pH 6.8), glycerol (48%), SDS (6%), β-mercaptoethanol (6%), and
bromophenol (0.03%). Cell lysates were denatured by heating before being applied to
SDS-PAGE gel.

After electrophoresis, proteins were transferred to nitrocellulose

membranes, blocked for 1 h in blocking solution (1-5% BSA in TBST buffer), and
incubated with specific primary antibodies overnight at 4°C. Primary antibodies were
detected with HRP-conjugated secondary antibodies, and antibody-protein complexes
were visualized using ECL (Pierce Biotech).
For immunofluorescence, 2.0 x 104 cells were seeded onto glass bottom culture
dishes (MatTek) and subjected to the appropriate treatments as described in the relevant
sections. Immunofluorescence assays were carried out according to standard methods as
described by others [17, 70]. Briefly, cells were fixed with 1% paraformaldehyde in 0.1
M sodium phosphate buffer, pH 7.3 for 10 min at RT. Cells were washed in 1X HBBS,
permeabilized by incubating with 0.01% Tween-20/HBBS for 10 min, and then washed
again with 1X HBBS. After the last wash, cells were blocked using blocking buffer (1%
BSA, 2% normal serum, 0.1% Tween-20 in PBS) for 30 min; blocking solution contained
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normal serum from the animal in which the primary antibody was generated. Once
blocking was complete, the cells were incubated with specific primary antibodies
overnight at 4°C. Bound antibody was visualized under the microscope (Leica SP2
confocal laser-scanning microscope, Leica Microsystems, Wetzlar, Germany) by
incubating for 1 h with secondary antibody labelled with Alexa Fluor 568 [Tetramethyl
Rhodamine Iso-Thiocyanate (TRITC)]. To visualize the nucleus, cells were exposed for
5 min at RT to a concentration of 300 nM DAPI (4', 6-diamidino-2-phenylindole,
dilactate) in HBBS. DAPI was prepared and diluted based on manufacturer’s instructions
(Invitrogen). After washing, cells were mounted using ProLong Gold Antifade reagent
(Invitrogen).

Dishes were sealed and allowed to dry overnight before imaging.

Additionally, both positive and negative controls were prepared and imaged alongside the
samples to correct for any background fluorescence and to serve as controls for
quantitative analysis. Images were captured using confocal microscopy (Leica SP2
confocal laser-scanning microscope, Leica Microsystems) with a 63x oil objective lens
(NA 1.32) and an automated stage.

Immunofluorescence quantitation
Immunofluorescence images were analyzed using NIS-Elements software (AR v. 3.1)
(Nikon Instruments). For each sample, image stacks (z-series) were acquired for 3 fields
with a step size of 0.5 µm. The percentage of co-localization was calculated using
Pearson’s correlation with a perfect correlation of 1 as compared to the internal control.
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Results and Discussion
HEK293T cells are frequently used to exogenously express target proteins for
analyses of protein-protein interactions, subcellular localization, etc. Two days prior to
transfection, cells were cultured in complete growth media under standard conditions [62,
63, 64] and a plasmid containing ATP10C and GFP (Origene) was transfected into
HEK293T cells using TurboFectin transfection reagent (Origene). For the GLUT4 colocalization, a GLUT4-RFP plasmid was co-transfected along with the ATP10C-GFP
plasmid. Without a good antibody available for ATP10C, this technique allowed us to
finally show a protein band at the expected molecular weight, about 165 kD (cDNA of
Atp10c is approximately 4.5 kb) (Figure 1).
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195 kD (165+30 kD)
Mock

48h

24h

Figure 1: ATP10C-GFP expressed in HEK293T cells
ATP10C expression was examined by Western immunoblotting using HEK293TATP10C-GFP total proteins collected in RIPA buffer at 24 h and 48 h post-transfection.
The 30kD molecular weight corresponds to the GFP fragment of the plasmid, while the
165 kD molecular weight is the expected size of ATP10C. Modified from “Turbofectin”,
Origene Technologies, Inc [68].
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Using immunofluorescence and confocal microscopy, we were able to show that
the ATP10C fusion protein localized to the plasma membrane of HEK293T cells (Figure
2). Similar studies using confocal immunofluorescence microscopy showed that
ATP8B1, ATP8B2 and ATP8B4, all members of the same ATPase family as ATP10C,
localized primarily at the plasma membrane. Additionally, ATP8A1 displayed a perinuclear staining and co-localized with the Golgi-marker
formiminotransferasecyclodeaminase indicating expression in the Golgi complex. When
expressed at very high levels, these type 4 ATPases also showed nuclear-envelope and
reticular staining that coincided with the endoplasmic reticulum (ER) marker protein,
disulfide isomerase [26].
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Control-GFP

ATP10C-GFP

Images courtesy of J. Dunlap, Advanced Microscopy and Imaging Center, UTK.

Figure 2: Localization of ATP10C-GFP in HEK293T cells
ATP10C localization was determined by immunofluorescence microscopy using
HEK293T-ATP10C-GFP cells. HEK293T cells were transfected with an ATP10C-GFP
expression plasmid; a control-GFP plasmid (pMax) was also transfected into HEK293T
cells to serve as a positive control. All samples were fixed at a designated time point (48
h). Confocal images were captured on a Leica SP2 laser scanning confocal microscope
(Leica Microsystems, Wetzlar, Germany) with a 63x oil objective lens (NA 1.32). For
each sample, image stacks (z-series) were acquired for 3 fields with a step size of 0.5 µm.
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Based on these findings, we sought to co-localize ATP10C with known
subcellular markers from a subcellular localization antibody kit (Cell Signaling).
Currently, none of the antibodies tested co-localized with ATP10C suggesting that
ATP10C does not localized in the microtubules (β-tubulin), the ER (Calnexin), or the
endosome (Rab5) (Figure 3). This makes sense as these proteins are expressed solely in
specialized compartments of the cell and not around the plasma membrane or in the Golgi
network. Based on these results it does not appear that like many other ATPases,
ATP10C localizes to the ER or endosomes. When we co-transfected ATP10C-GFP with
a GLUT4 expression plasmid, it appears as though there is some overlap in their
localization (Figure 3). It is difficult to quantify this co-localization as the transfection of
both plasmids into the HEK293T has relatively low efficiency. As such, this procedure
needs to be optimized for maximum transfection efficiency before any further
conclusions can be made. However, by measuring a particular region of interest (ROI)
within a given field, we were able to calculate percentage of co-localization of ATP10C
and GLUT4. Pearson’s correlation of the two proteins yielded an 81% co-localization.
This value was obtained when comparing the image with significant overlap with an
image that had none (0.1% co-localization). Future work to see if ATP10C co-localized
with any of the known Golgi, VAMP, and SNARE markers should be conducted.
Unfortunately, we cannot use the HEK293Tcells to perform these experiments as these
cells are non-responsive to insulin and therefore, do not contain the machinery necessary
to form and/or translocate glucose storage vesicles (GSVs). As such, another
transfectable in vitro cell models must be found and optimized for these experiments.
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β-tubulin+ATP10CGFP

WGA-ATP10C-GFP

ATP10C-GFP

Calnexin+ATP10CGFP

Rab5+ATP10C-GFP

GLUT4-RFP+ATP10CGFP

Images courtesy of J. Dunlap, Advanced Microscopy and Imaging Center, UTK.

Figure 3: Co-localization of ATP10C-GFP with known protein markers
ATP10C localization was determined by immunofluorescence microscopy using
HEK293T-ATP10C-GFP cells, or HEK293T cells co-transfected with both plasmids,
ATP10C-GFP and GLUT4-RFP. Cells transfected with the ATP10C-GFP plasmid only
were immunostained with primary polyclonal antibodies and labeled using the
appropriate secondary antibodies conjugated with TRITC. Confocal images were
captured on a Leica SP2 laser scanning confocal microscope (Leica Microsystems,
Wetzlar, Germany) with a 63x oil objective lens (NA 1.32). For each sample, image
stacks (z-series) were acquired for 3 fields with a step size of 0.5 µm.
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Given the significant results of the ATP10C, GLUT4 co-localization, we wanted
to explore further the possible interaction of these proteins and their plausible joint role in
DIO and T2D. As a possible consequence and/or cause of DIO, insulin increases
triglyceride storage in adipocytes, inhibits of the breakdown of fat, and stimulates
adipocyte differentiation, thus increasing the level of adipose tissue [71, 72]. An increase
in adiposity additionally raises various secreted adipokines which in turn cause secondary
effects in liver and skeletal muscle. An aberration in any of these processes will result in
IR. IR resistance in skeletal muscle like adipose tissue can be caused by alterations in
insulin binding and signalling that effect glucose and lipid metabolism. Insulin sensitivity
improves when insulin binds to its membrane bound receptor, eliciting downstream
effects that lead to the uptake of glucose from the blood.
Based on previous results from our laboratory, Atp10c-heterozygotes represent a
novel model of DIO and T2D, to further validate this model, we examined the expression
of Atp10c in two mice models of obesity, one genetic and one diet-induced. Since we
hypothesize that Atp10c/ATP10C plays a role in DIO and T2D, we wanted to examine its
expression in key tissues (skeletal muscle, adipose and liver tissues) responsible for
glucose homeostasis. As shown in Figure 4, there is relatively high change of expression
in the skeletal muscle (3.78 fold) as compared to adipose and liver tissues in the DIO
model. In the ob/ob mice, Atp10c expression was highest in fat (2.94 fold), then skeletal
muscle (2.44 fold) when compared to their age and sex matched wild type controls as
indicated in Figure 5. While none of these tissues show significant expression of Atp10c
when compared to their age and sex-matched controls, we are still assured that given the
expression profiles of the skeletal and fat tissues, this novel gene is important in both
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DIO and T2D and its functional investigation involving these disease processes is not
only warranted, but is necessary.
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Figure 4: Atp10c mRNA is expressed in a DIO mouse model
Atp10c expression was examined by qPCR in mouse skeletal muscle (SKM), in mouse
epididymal fat (FAT), and in mouse liver (LIVER) tissues after 20 weeks on a high fat
diet. Gapdh served as an internal control. The expression of Atp10c is denoted as an
arbitrary unit (A.U.) and is represented normalized to Gapdh.
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Figure 5: Atp10c mRNA is expressed in a genetic mouse model of obesity (ob/ob)
Atp10c expression was examined by qPCR in mouse skeletal muscle (SKM), in mouse
epididymal fat (FAT), and in mouse liver (LIVER) tissues. Gapdh served as an internal
control. The expression of Atp10c is denoted as an arbitrary unit (A.U.) and is
represented normalized to Gapdh.
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Overall, in the genetic model of obesity (ob/ob), Atp10c expression was highest in
adipose tissue (2.94 fold) suggesting that this gene may play an important role in
adiposity. This pronounced effect on the fat can then in turn affect various other tissues
in the body such as skeletal muscle and the liver. Studies in our laboratory have further
demonstrated that Atp10c encodes an APLT and is a type 4 P-type ATPase related to
lipid trafficking and maintenance of the phospholipid asymmetry and fluidity of the
plasma membrane. Moreover, Atp10c seems to be involved in modulating body fat.
Evidence continues as mice inheriting a maternal deletion of Atp10c are considered a
model of DIO and T2D, since they develop more hyperinsulinemia, IR, and NAFLD than
mice inheriting the same deletion paternally. Similarly, simulations of maternal deletion
of Atp10c indicated an anabolic metabolism consistent with the known clinical
phenotypes of obesity [12].
For the DIO mice, the expression of Atp10c was higher in the skeletal muscle
(3.78 fold), so changes in diet appear to effect the expression of Atp10c validating its role
in DIO and other disorders that can arise like IR and T2D. Moreover, these results
demonstrate that the diet induced greater responses in skeletal muscle than it does in fat
tissue. In a 2004 study, Dhar et al [72] showed that when these mutant mice were placed
on a high-fat diet (45% energy), body weight, adiposity index, and plasma insulin, leptin
and triglyceride concentrations were significantly greater in the mutants compared with
their age and sex-matched control mice fed the same diet. Additionally, glucose and
insulin tolerance tests were performed on these mice, and the mutants had altered glucose
tolerance and insulin response compared with controls resulting in IR. Moreover, routine
gross and histological evaluations of the liver, pancreas, adipose tissue, and heart were
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performed and histological evaluation showed micro and macrovesicular lipid deposition
within the hepatocytes that was more severe in the Atp10c mutant mice than in agematched controls.
Importantly, the 2004 Dhar et al study [72] focused primarily on the obesity
issues and therefore, studies were exhaustive for adipose tissue. Future work on these
Atp10c-mutant mice needs to be conducted to focus on the skeletal muscle consequences
of this genetic aberration as our results from this study and numerous others show that
skeletal muscle is a vital player in both glucose and lipid metabolism. Moreover, all these
results give direct evidence from the Atp10c mutant mice demonstrating the significance
of both genetics and environmental conditions in the disease states of DIO and T2D.

Conclusions
Atp10c/ATP10C is a putative phospholipid translocase that Atp10c plays a role in
the maintenance of the phospholipid asymmetry and fluidity of the plasma membrane. As
such, loss of Atp10c/ATP10C function upsets the normal membrane environment and
perturbs glucose and lipid metabolism. To understand the role of type 4 P-type ATPases,
it is important not only to study the cellular consequence when they are non-functional,
but also to elucidate the specific conditions required for their activation as well as their
(subcellular) localization [27]. Our results concluded that ATP10C, a 165 kD protein,
localizes in or around the plasma membrane and appears to co-localize with GLUT4 as
well. In view of the data presented here and the literature discussed, we are encouraged in
using this model to dissect metabolic pathways involved in glucose and lipid metabolism
thus gaining a better understanding of the underlying molecular mechanisms through
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biological characterization. Also, in the present study, we established the legitimacy of
our gene as a good candidate for DIO and T2D, as demonstrated by Atp10c’s increased
expression in two mice models of obesity, one a genetic model and the other an
environmental one. Specific targeted experiments to generate adipose tissue and skeletal
muscle-specific transgenic mice and to then, assess protein expression of target genes are
projects that should be initiated in the future.
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Biological Characterization
Abstract
Atp10c/ATP10C is a strong candidate gene for DIO and T2D. To identify
molecular and cellular targets of ATP10C, Atp10c mRNA expression was altered in vitro
in C2C12 and L6-G4myc skeletal muscle myotubes transiently by transfection with an
Atp10c-specific siRNA. During basal and insulin-stimulated conditions, results show that
several MAPK proteins are altered both in vitro and in vivo. The PI3K pathway was also
shown to be effected as key proteins in that pathway were also altered during both
experimental states. Additionally, GLUT1 was significantly up-regulated; no changes in
GLUT4 expression were observed. Glucose uptake assays revealed that insulin
stimulation caused a significant 2.54-fold decrease in 2-DOG uptake in transfected cells.
Results from GLUT4 translocations assays show that silencing of Atp10c is altering
normal GLUT4 regulation, most likely playing a role in GLUT4 endocytosis. The
involvement of MAPK proteins was confirmed using the specific inhibitor SB203580,
which down-regulated the expression of native and phosphorylated MAPK proteins in
transfected cells without any changes in insulin-stimulated glucose uptake. Taken
together, all these results indicate that Atp10c regulates glucose metabolism, with
strongest evidence supporting its action on the MAPK pathway, specifically p38, and
thus, plays a significant role in the development of IR and T2D.
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Introduction
The incidence of T2D and DIO is increasing rapidly and reaching epidemic
proportions throughout the world populations. Although the cause of T2D remains
unclear, it is known that IR is closely related to the development of the disease. IR is
characterized by a failure of the hormone, insulin, to result in efficient glucose disposal,
and particularly produce its normal increase in glucose transport in target tissues namely
skeletal muscle and adipose tissue. Defective glucose uptake in skeletal muscle and
adipose tissues plays a major role in causing IR and glucose intolerance symptoms
associated with T2D. In humans, skeletal muscle accounts for nearly 40% of the body’s
mass and serves as the main tissue involved in glucose uptake during insulin stimulation.
Several researchers have established that glucose consumption in skeletal muscle
decreases with T2D. This reduced glucose consumption can be the result of impaired
transduction of insulin signals, such as IRS phosphorylation; PI3K activity; MAPK
activity; insulin-responsive glucose transporters, namely GLUT4; and/or other insulinindependent mechanisms [18]. Therefore, a detailed analysis of insulin signaling at the
cellular and molecular level is critical to understand the pathogenesis of T2D associated
with DIO. Cell culture models have been used extensively in research to investigate
numerous disease states including IR and T2D. As skeletal muscle is the target tissue of
interest for glucose clearance and as such a desirable object of study in regards to IR and
T2D, the cell culture models used must exhibit similar characteristics and behaviors of
the tissue under investigation. For our experiments, two skeletal muscle models were
chosen, murine C2C12 and rat L6. Specifically, rat L6 cells over-expressing a GLUT4-
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myc tag were used for analysis of the PI3K pathway and its association with GLUT4
translocation.
Heterozygous Atp10c mice present with the disease states of IR and DIO, as well
as a host of other related disorders, including hyperlipidemia and hyperinsulinemia.
Previous research using these mice indicates that the Atp10c gene appears to be a strong
candidate gene for DIO and T2D [72]. Atp10c is a putative phospholipid translocase or
“flippase,” which encodes for a type 4 P-type ATPase. Atp10c maps to the p-locus on
mouse chromosome 7, to a region of a quantitative trait locus associated with body
weight, body fat and diabetic phenotypes. The human ortholog, ATP10C, maps to the
syntenic region on chromosome 15q12 and is also associated with an elevated BMI [36,
73]. Moreover, microarray gene profiling on Atp10c heterozygous mice indicated
significant changes in the mRNA expression of factors involved in insulin dependent and
insulin-independent glucose uptake [2].
Although flippases, like Atp10c, have been studied for many years, their exact
character and function remain unclear. These proteins are believed to maintain the
asymmetry of the lipid bilayer by translocating specific phospholipids from one leaflet to
the other and vice versa [7], but they may also participate in the formation of transport
vesicles [74]. Moreover, deficiencies in these proteins have been shown to cause defects
in lipid metabolism and have been implicated in the disease states of DIO, T2D, and
NAFLD [72]. Not much is known about the role of ATP10C in regulating IR in skeletal
muscle, if any, and its possible molecular and cellular targets have not been investigated.
In view of the above literature, we hypothesized that the type 4 P-type ATPase,
ATP10C has an important role in glucose metabolism. Since ATP10C is a
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transmembrane protein it might exert its effect via multiple signaling pathways; (1) acting
solely at the plasma membrane to maintain the non-random distribution of phospholipids,
thus contributing to a proper membrane environment for normal protein sequestration and
function, (2) acting at the plasma membrane affecting the biogenesis of membrane
vesicles important for plasma membrane delivery and/or retrieval of glucose transporter
proteins in basal and insulin-stimulated states, and (3) acting directly on the expression,
translocation and/or function of glucose transporter proteins themselves. Based on the
observed phenotype of glucose and lipid metabolic abnormality in Atp10c-heterzygous
mice, we explored Atp10c/ATP10C’s role in these important pathways to address its
plausible function. Since the MAPK pathway is known to be a key signaling cascade
which mediates glucose clearance/uptake by the skeletal muscle in presence or absence of
insulin, we tested whether the MAPKs, in general, are the targets of ATP10C. To prove
our hypothesis, specific objectives were to (a) establish a tissue culture systems of mouse
skeletal muscle wherein endogenous expression of Atp10c could be monitored, (b) alter
the endogenous level of Atp10c expression by siRNA and, (c) measure functional
outcomes i.e. glucose uptake and GLUT4 translocation and assess changes in expression
of MAPKs involved in this process. Moreover, since the MAPK pathway is known to be
a key signaling cascades which mediate glucose clearance/uptake by the skeletal muscle
in presence or absence of insulin, we tested whether the products of this pathway are
potential targets of ATP10C, and whether or not the activity of the PI3K pathway, the
insulin-dependent pathway, is altered by Atp10c-silencing.
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Materials and Methods
Mouse skeletal muscle cell line C2C12, a commercially-available cell line, was
kindly provided by Dr. Seung Baek, College of Veterinary Medicine, the University of
Tennessee, Knoxville, TN, USA. Rat L6 muscle cells stably expressing GLUT4 with an
exofacial myc-epitope (L6-G4myc) were commercially obtained from Dr. Amira Klip
(The Hospital for Sick Children, Toronto, Canada). DMEM containing 4.5 mg/L glucose
and 4.5 mM/L L-glutamine, antibiotics (100 IU/ml penicillin and 100 μg/ml
streptomycin), ABsolute Blue SYBR Green ROX quantitative PCR mix, BCS, and RIPA
buffer were from Thermo Fisher Scientific (Waltham, MA). DMEM with 1% antibiotics
and 10% BCS is furthermore referred to as the complete growth media. Horse serum, 2DOG, pi cocktail in DMSO solution, MAPK inhibitor SB203580, and human insulin
solution (10 mg/mL in HEPES, pH 8.2) were from Sigma Aldrich (St. Louis, MO). αMinimum essential medium (α-MEM) containing 5.5 mM glucose was obtained from
Gibco (Grand Island, NY) and 10% FBS was purchased from HyClone Laboratories
(Grand Island, NY). BCA and an ECL Western Blotting Detection Kit were purchased
from Pierce Biotech Inc. (Rockford, IL) and used in protein experiments. Primary
antibodies (p38, phospho-p38, JNK, phospho-JNK, ERK1/2, phospho-ERK1/2, phosphoAkt2 (Ser473) and phospho-Akt2 (Ser/Thr) referred hereafter as AS160) as well as the
secondary antibody, HRP-conjugated anti-rabbit IgG, were obtained from Cell Signaling
Technology (Danvers, MA). PY20 and its specific secondary antibody (goat anti-mouse)
were purchased from BD BioSciences, Sparks, MD). Caveolin-1 was used as an
immunoblot control and was purchased from Santa Cruz Biotechnologies (Santa Cruz,
CA) along with primary antibodies for PI3K, Akt2, myc, GLUT1, and GLUT4. The
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secondary antibody, HRP-conjugated anti-goat IgG, was also obtained from Santa Cruz
Biotechnologies. HiPerfect transfection reagent, Atp10c-specific siRNA constructs,
RNeasy Mini Kit and QuantiTect primer assays for myogenin, MyoD and Atp10c were
from Qiagen (Valencia, CA). Quantitative PCR primers specific for mouse
glyceraldehyde 3-phosphate dehydrogenase (Gapdh) were designed using the Primer 3
program (http://primer3.sourceforge.net) and were commercially obtained from Operon
(Huntsville, AL). The iScript cDNA synthesis kit was acquired from Bio-Rad
Laboratories (Hercules, CA). All immunofluorescence materials (protein blocks [normal
goat], negative control [normal goat] and antibody diluent) were purchased from
BioGenex (San Ramon, CA). All the immunocytochemistry materials (Odyssey Blocking
Buffer and infrared-conjugated secondary antibody) were purchased from LI-COR
Biosciences (Lincoln NE). Syto60 was purchased from Molecular Probes (Eugene, OR).
Millicell EZ slides from Millipore (Billerica, MA) were used for the immunofluorescence
studies. Secondary antibody specific for immunofluorescence application, Alexa Fluor
568 donkey anti-goat as well as Prolong Gold Antifade reagent were purchased from
Invitrogen (Carlsbad, CA).

Cell culture and treatments
C2C12 myoblasts were cultured as described elsewhere [70]. Roughly 2.0 x 105 cells
were seeded in a 60-mm dish or a single well of a 6-well plate. They were maintained at
37°C and 5% CO2 in complete growth media. Cells at 70% confluency were
differentiated in the presence of 2% horse serum-enriched media for 3–5 days.
Completely differentiated myotubes (days 3–5) were either subjected to various
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treatments described in the relevant sections or harvested for use in subsequent
experiments. L6-G4myc cells were cultured as previously described [76]. Myoblasts were
maintained and differentiated into multinucleated myotubes with the addition of 2% FBS.
All studies with the L6-G4myc cells used myotubes between 4-6 days post-initiation of
differentiation. Cells were serum starved for 30 min before all experiments. During the
final 20 min of these incubations, cells were left in either the basal state or were acutely
stimulated with 100 nM insulin.

Mouse treatment and sample collection
Mice containing radiation-induced chromosomal deletions of Atp10c on mouse
chromosome 7 located at the pink-eyed dilution locus were generated and maintained [77,
78]. Heterozygous mice inheriting the deletion maternally that were fed a high-fat diet as
were heterozygotes inheriting the Atp10c-deletion paternally which served as the
controls. After feeding both sets of mice for 4 and 12 weeks, the mice were euthanized
and tissues collected. The mouse studies were approved by the IACUC at the University
of Tennessee.

siRNA transfection
Three different siRNA oligonucleotides against Atp10c were commercially obtained
(Qiagen); one was generated from the sequence at the 3′ end of the Atp10c gene,
SI00906220 (sense: r[CCU GGG UAU UGA AAC CAA A]dTdT and antisense: r[UUU
GGU UUC AAU ACC CAG G] dTdG), the second, SI00906213, and third, SI00906206,
were generated from the sequence at the 5′ end (sense: r[CGU CUU UGC UGC AAU
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GAA A]dTdT and antisense: r[UUU CAU UGC AGC AAA GAC G]dGdA). C2C12 and
L6-G4myc myotubes were transiently transfected with and Atp10c-specific siRNA using
HiPerfect transfection reagent (Qiagen) according to the manufacturer’s instructions.
Myotubes transfected with siRNA were either harvested or treated with the reagents
indicated in the relevant sections and/or used for functional assays.
In the first experiment, the optimum concentration and time of knockdown for
each siRNA used was determined. Briefly, HiPerfect transfection regent and siRNAs
were mixed at various concentrations (0, 50, 100, and 200 nM) to form a complex. The
transfection complexes were then applied to designated cells and incubated for 24, 48, or
72 h before subsequent analysis. C2C12 and L6-G4myc myotubes demonstrating
efficient Atp10c knockdown as quantitated by qPCR and, therefore, used in all further
experiments were designated as C210c/- and L610c/-. Mock transfected (i.e. transfected
with HiPerfect only) C2C12 and L6-G4myc myotubes (C2wt and L6wt respectively)
were used as corresponding controls.

RNA, cDNA synthesis, and qPCR
The following procedures were performed as described elsewhere [2, 65, 66]. Cells were
washed with ice cold 1X HBBS and total RNAs were isolated using RNeasy Mini RNA
kit (Qiagen), according to the manufacturer’s instructions. Single-stranded cDNA was
synthesized using the iScript cDNA synthesis kit (Bio-Rad), and amplified using genespecific primers by qPCR with mouse Gapdh as the housekeeping gene. All mRNA
expressions were achieved by qPCR using ABsolute SYBR Green ROX quantitative
PCR mix on the Strategene Mx3005P with MxPro analysis software under the following
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PCR conditions: 1 cycle of 50°C for 15 min and 95°C for 2 min, followed by 40 cycles of
95°C for 25 s, 52°C for 25 s and 72°C for 1 min. The relative abundance of target gene
expression was calculated using the 2-ΔΔCT and standard curve method, with ΔΔCT
being the difference between CT of the target gene normalized with respect to the Gapdh
CT [67].

Preparation of cellular extracts and immunoblotting
Total cell lysates were isolated using RIPA buffer according to standard methods [65, 66,
69]. Briefly, cells were washed twice with 1X HBBS and lysed in RIPA buffer containing
pi at 4°C for 30 min. Lysates were centrifuged at 16,000g for 10 min at 4°C. Protein
estimation was performed using the BCA kit (Pierce Biotech), with an internal standard
according to the manufacturer’s instructions.
Immunoblot analysis was carried out according to standard procedures [66, 69].
Equal concentrations (25−100 μgs) of proteins were resolved on 10% SDS-PAGE, using
5X Laemmli sample buffer containing Tris-HCL (375 mM, pH6.8), glycerol (48%), SDS
(6%), beta-mercaptoethanol (6%), and bromophenol (0.03%). Cell lysates were denatured
by heating before being applied to SDS-PAGE gel unless otherwise noted as in the case
of GLUT1 and GLUT4 investigation. After electrophoresis, proteins were transferred to
nitrocellulose membranes, blocked for 1 h in blocking solution (1-5% BSA in TBST
buffer), and incubated with specific primary antibodies overnight at 4°C. Primary
antibodies were detected with HRP-conjugated secondary antibodies, and antibodyprotein complexes were visualized using ECL (Pierce Biotech). Results are expressed as
the ratio of target protein expression to that of an internal loading control, caveolin-1.
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Immunofluorescence and immunocytochemistry
For immunofluorescence, 2.0 x 104 cells were seeded onto 4-well chamber slides
(Millipore) and subjected to the appropriate treatments as described in the relevant
sections. Immunofluorescence assays were carried out according to standard methods as
described by others [17, 75]. Briefly, cells were fixed with 1% paraformaldehyde in 0.1
M sodium phosphate buffer, pH 7.3 for 10 min at RT. Cells were washed in 1X HBBS,
permeabilized by incubating with 0.01% Tween-20/HBBS for 10 min, and then washed
again with 1X HBBS. After the last wash, cells were blocked using blocking buffer (1%
BSA, 2% normal serum, 0.1% Tween-20 in HBBS) for 30 min. Blocking solution
contained normal goat serum, the animal in which the primary antibody was generated.
Once blocking was complete, the cells were incubated with specific primary antibodies
overnight at 4°C. Bound antibody was visualized under the microscope (Nikon Ti-E
Eclipse, Nikon Instruments, Melville, NY) by incubating for 1 h with secondary antibody
labeled with Alexa Fluor 568 (TRITC). To visualize the nucleus, cells were exposed for 5
min at RT to a concentration of 300 nM DAPI in HBBS. DAPI was prepared and diluted
based on manufacturer’s instructions (Invitrogen). After washing, cells were mounted
using ProLong Gold Antifade reagent (Invitrogen). Slides were sealed and allowed to dry
overnight before imaging. Additionally, both positive and negative controls were
prepared and imaged alongside the samples to correct for any background fluorescence
and to serve as controls for quantitative analysis. Images were captured using an
epifluorescence microscope (Nikon Instruments) with a 60x objective lens (NA 1.49) and
an automated stage.

65

For immunocytochemistry, myotube GLUT4myc labeling was performed as
previously

described

[76].

Briefly,

myotubes

were

fixed

with

2%

paraformaldehyde/HBBS. After fixation, cells were left un-permeabilized and blocked in
Odyssey Blocking Buffer (LI-COR Biosciences). The samples were then incubated in
primary myc antibody (Santa Cruz Biotechnology) overnight, washed and incubated with
an infrared-conjugated secondary antibody (LI-COR) for 1 h. Images were then taken and
quantified for further analysis.

Glucose uptake
Glucose uptake in myotubes was measured as previously described [66]. Briefly,
myoblasts were plated in 6-well cell culture plates at a density of 2 x105 cells/well and
allowed to differentiate under normal conditions. After differentiation, cells were washed
with IX HBBS and serum starved in DMEM only for 3−5 h. Cells were stimulated with
100 nM insulin in DMEM for 30 min at 37°C. Each 6-well plate was set up so that wells
1, 2, and 3 did not contain insulin and wells 4, 5, and 6 did contain insulin. Insulin
induction was stopped by washing the cells twice with 1 ml Krebs-Ringer HEPES (KRP)
(121 mM NaCl, 4.9 mM KCl, 1.2 mM MgSO4, 0.33 mM CaCl2, 12 mM HEPES) minus
glucose at RT. Cytochalasin B (5 μl of 1 mM stock/1 ml cocktail) was used to normalize
for non-specific glucose uptake. Glucose uptake was determined after the addition of 3H2-deoxyglucose (1 μl of 10 Ci/mmol stock/1 ml cocktail) in KRP buffer at 37°C for 5
min. Incorporation was terminated by washing the cells twice with 1 ml ice cold KRP
plus 25 mM glucose. Cells were lysed on ice for 30 min with RIPA buffer. Following
incubation, 0.5 ml cell lysates were mixed with 10 ml scintillation fluid (Scintiverse) and
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subjected to liquid scintillation counting. For protein quantitation (BCA method, Pierce
Biotech), 250 μl of the lysate was used and processed according to the manufacturer’s
instructions. Glucose uptake was expressed as disintegrations per minute per microgram
of total protein (dpm/μg). Data is reported as the glucose uptake stimulation expressed as
the ratio of dpm/μg of total protein in presence of insulin to that in the absence of insulin.

Densitometry analysis
Relative densitometry analyses of the immunoblots were determined using Image J
(http://rsb.info.nih.gov/ij/index.html) analysis software. By giving an arbitrary value of
1.0 to the respective control sample (caveolin-1) of each experiment, a ratio of relative
density was calculated for each protein of interest.

Immunofluorescence and immunocytochemistry quantitation
Immunofluorescence images were analyzed using NIS-Elements software (AR v. 3.1)
(Nikon Instruments). For each sample, 9 dual-channel images were captured and stitched
together to form a large image (3x3). Mean fluorescence intensity per cell was calculated
(MFI per cell = total image fluorescence/cell count). Cell count was determined using a
nuclear stain (300 nM DAPI in HBBS).
For immunocytochemistry, images were collected and quantified with the
Odyssey system as previously described [76]. Immunofluorescent intensity was
normalized to intensity from Syto60, a fluorescent nucleic acid stain (Molecular Probes).
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Statistical analysis
The data are expressed as mean ± SE. For comparison of two groups, P values were
calculated using the two-tailed paired Student t test. In all cases P < 0.05 was considered
statistically significant and P < 0.10 was indicative of a trend.

Results and Discussion
To alleviate whole-animal complexities, C2C12, a mouse skeletal muscle cell
line as well as a rat skeletal muscle cell line, L6, overexpressing a GLUT4myc tag were
chosen as in vitro models to identify molecular and cellular targets of Atp10c/ATP10C
and then assess its biological role, if any, in insulin signaling and glucose metabolism
[20, 21, 22, 23, 79]. Under permissive conditions, C2C12 and L6-G4myc myoblasts
undergo differentiation to form myotubes. Differentiation of C2C12 myoblasts to
myotubes was confirmed by visual inspection (Figure 6), as well as by monitoring the
expression of skeletal muscle-specific mRNAs for MyoD and myogenin [80].
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Figure 6: C2C12 myoblasts differentiate to myotubes
Skeletal muscle differentiation was examined in C2C12 cells. Cells were seeded into 60
mm dishes and allowed to attach. After 24 h, differentiation was stimulated via the
addition of horse serum (2%) enriched media. Differentiation media was changed every
48 h until the process was complete (about 3-5 days). Images were produced on Digital
USB2 Microscope (Westover Scientific Inc., Mill Creek, WA) using Micron imaging
software.
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C2C12 cells were collected on days 1, 3, and 5 during the differentiation process.
Cells collected at day 1 represent the myoblasts, which are then stimulated to differentiate
into myotubes by days 3-5. The activation of cell differentiation is characterized by the
expression of myogenic regulatory factors including MyoD and myogenin. After
proliferation, cells express myogenin which commits the myoblasts towards myogenic
differentiation. This is followed by the expression of additional factors including but not
limited to Myf-5 and MRF4, and permanent exit from the normal growth and
proliferation cycles. As expected and shown in Figure 7, the expression of myogenin
increased as C2C12 myoblasts were stimulated to differentiate (30% to 52%), and
decreased when differentiation was complete (20%). Similarly, qPCR showed that MyoD
expression increased dramatically on day 1 (172%), then steadily declined on days 3 and
5 (64% and 24%, respectively). Interestingly, Atp10c was expressed in both myoblasts
and myotubes, and its expression increased upon differentiation (42% to 64%) and
steadily decreased as myotubes were formed (47% on day 5). Changes in Atp10c
expression with differentiation were similar, but, not as striking as that of myogenin and
MyoD, ramifications of which are clearly beyond the scope of this study. The data thus
demonstrated the expression of Atp10c mRNA in C2C12 cells, and gave us an
opportunity to modulate its expression in both myoblasts and myotubes, both of which
can have significant consequences in insulin signaling pathways.
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Figure 7: Atp10c, myogenin, and MyoD mRNA is expressed in C2C12 cells
undergoing differentiation
Cells were collected at the above time points (Days 1, 3, and 5). MyoD, myogenin and
Atp10c gene mRNA expression was analyzed using qPCR. The expression of Atp10c,
myogenin, and MyoD is denoted as percentages (%) as normalized to Gapdh. Data
represents three independent experiments with each sample repeated in triplicate.
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One of the limitations of global gene-targeting and whole-animal approach is that
adaptations over time might occur, possibly producing secondary phenotypes that are not
directly linked to the mutation. In this case, the role of Atp10c could be shown either by
generating knockout mice or using specific inhibitors against ATP10C. Since no
inhibitors are available, and to avoid whole-animal complexities in transgenics, we
modulated Atp10c expression in vitro in both C2C12 and L6-G4myc cells transiently by
transfecting them with three independent and commercially available Atp10c specific
siRNAs (Qiagen). ATP10C is a putative transmembrane domain protein and as such a
good antibody against ATP10C has yet to be generated, making experiments to study
ATP10C challenging. Therefore, in this analysis, changes in Atp10c expression were
determined solely at the mRNA level by qPCR using QuantiTect primer assays (Qiagen).
Out of the three siRNAs tested, only one, SI00906220, resulted in a significant
knockdown of ≥70% (Figure 8 and Figure 9).
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Figure 8: Optimization of siRNA in C2C12 myotubes at a concentration of siRNA
(SI00906220) 50nM and a time point of 24 h gives the most efficient transfection
condition.
C2C12 myoblasts were differentiated into myotubes. Myotubes were transfected at each
concentration of siRNA (SI00906220) (0, 50, 100, and 200 nM) collected at the above
time points (24, 48, and 72 h). Gapdh (housekeeping gene) and Atp10c gene mRNA
expression was analyzed using qPCR. The percentage of knockdown was calculated at
each concentration and time point based on the expression of the mock-transfected (0
nM) samples (*P < 0.7 based on Qiagen recommendations). Data represents three
independent experiments with each sample repeated in triplicate.
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Figure 9: Optimization of siRNA in L6-G4myc cells at a concentration of siRNA
(SI00906220) 50nM and a time point of 48 h gives the most efficient transfection
condition.
L6-G4myc myoblasts and myotubes were transfected at each concentration of siRNA
(SI00906220) (0 and 50 nM) collected at the above time points (24 and 48 h). Gapdh
(housekeeping gene) and Atp10c gene mRNA expression was analyzed using qPCR. The
percentage of knockdown was calculated at each concentration and time point based on
the expression of the mock-transfected (0 nM) samples (*P < 0.7 based on Qiagen
recommendations). Data represents three independent experiments with each sample
repeated in triplicate.
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As shown in Figure 8, significant knockdowns (70 to 100%) were observed in all
samples with the exception of 200 nM, 72 h for C2C12 myotubes. Higher concentrations
and longer time periods resulted in cell death and poor quality of cells (as judged
visually). Optimization of concentration and time of transfection results indicated that a
concentration of 50 nM of siRNA (SI00906220) and a time point of 24 h be used for all
subsequent experiments in C2C12 myotubes. Similarly, a siRNA (SI00906220)
concentration of 50nM and a time point of 48 h were found to be optimal for the L6G4myc myotubes (Figure 9). Gapdh was used as the housekeeping gene, and no
significant mRNA changes in its corresponding expression in transfected cells were
observed. Results thus suggest that changes in Atp10c expression after transfection with
siRNA (SI00906220) were not an artifact, and there was no deleterious effect on C2C12
or L6-G4myc myotubes due to Atp10c silencing. All further experiments were carried
out under these conditions in wild-type C2C12 (C2wt) and L6-G4myc (L6-G4myc wt)
and Atp10c-silenced C2C12 and L6-G4myc myotubes (C210c/-and L6-G4myc 10c/-)
simultaneously. Since these transfections are transient, Atp10c mRNA knockdown was
confirmed in each and every experiment (data not shown).
Previous experiments in our laboratory have shown that on a high fat diet, there is
a 35% decrease in glucose uptake in soleus muscle in Atp10c heterozygotes [2]. Based on
this finding, we next determined whether down regulation of Atp10c expression had a
similar effect in vitro. Glucose uptake was measured in C2wt and C210c/- myotubes in
basal (without insulin) and stimulated (100 nM insulin, 30 min) states. Fold change
representing the glucose uptake stimulation/reduction between the C2wt and C210c/- was
compared. As shown in Figure 10, insulin stimulation caused a significant 2.54-fold
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decrease in 2-DOG uptake in C210c/- cells (P < 0.05). Data thus complement the in vivo
findings, suggesting that Atp10c is necessary for insulin-stimulated glucose uptake in
skeletal muscle and its knockdown renders the myotubes insulin resistant.
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Figure 10: Glucose uptake in Atp10c-silenced C2C12 myotubes is decreased 2.5 fold
C2C12 myoblasts were differentiated into myotubes. Myotubes were transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM) at the designated time point (24 h).
Cells were then stimulated with insulin (100 nM, 30 min), and a 2-DOG uptake was
performed (*P < 0.05). Data is reported as the glucose uptake fold stimulation which is
expressed as the ratio of dpm/µg of total protein in presence of insulin to that in the
absence of insulin and indicated as arbitrary units (A.U.).
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Silencing Atp10c mRNA decreases cellular glucose uptake, which might be of
consequence to impaired insulin signaling. Insulin-induced glucose uptake into muscle
and adipose tissue involves a series of intracellular signaling cascades, culminating in
glucose disposal and metabolism [81, 82, 83, 84, 85, 86]. The possible mechanisms
include insulin-mediated activation of the insulin receptor and/or its downstream
molecules, ultimately effecting GLUT4 expression and translocation. Since these
processes are a complex interplay of a variety of proteins and because their changes have
not been studied in Atp10c-silencing, we sought to identify changes in the key proteins of
relevant signaling cascades, the PI3K and the MAPK pathway in the presence of any
insulin stimulation. Specifically, in the present study, the effect of Atp10c-silencing was
considered on three essential MAPKs: p38, JNK, and ERK1/2 in addition to PI3K key
proteins PI3K, Akt2, phospho-Akt2 (Ser473) and AS160. Additionally, proteins upstream of MAPK and PI3K, IRS-2, and IR-β, were examined. Total proteins isolated
from C2wt, C210c/-, L6-G4myc wt and L6-G4myc 10c/- myotubes were subjected to
immunoblot analysis while C2wt and C210c/- myotubes were further analyzed using
immunofluorescent techniques.
Under basal glucose uptake conditions for MAPK pathway analysis, results
indicated significant up-regulation of p38 (P = 0.02) and ERK1/2 (P = 0.04), and a
significant down-regulation of JNK (P = 0.001) and phospho-ERK1/2 (P = 0.05) in
C210c/- cells (Figure 11A-C). While not significant, results indicated a trend for an
increase in phospho-p38 (P = 0.1) (Figure 13A) and phospho-JNK (P = 0.06) (Figure
11C). Besides these signal transduction proteins, there was significant up-regulation of
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MyoD (P = 0.01), Actin (P = 0.02) (Figure 12A-B), and GLUT1 (P = 0.03) (Figure 13).
Most importantly, there was no significant change in GLUT4 expression (Figure 13).
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Figure 11A: MAPK proteins, p38 and phospho-p38, are significantly up-regulated
after Atp10c-silencing in C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes, then transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM) and collected at the designated time
point (24 h). Proteins were collected from these samples and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of p38 and phospho-p38 is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to Caveolin-1; *P<0.05,
#P<0.10.
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Figure 11B: MAPK proteins, ERK1/2 and phospho-ERK1/2, are significantly
altered after Atp10c-silencing in C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes, then transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM) and collected at the designated time
point (24 h). Proteins were collected from these samples and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of ERK1/2 and phospho-ERK1/2 is denoted as
arbitrary units (A.U.) and represented as the fold change normalized to Caveolin-1;
*P<0.05.
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Figure 11C: MAPK proteins, JNK and phospho-JNK, are significantly altered after
Atp10c-silencing in C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes, then transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM) and collected at the designated time
point (24 h). Proteins were collected from these samples and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of JNK and phospho-JNK is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to Caveolin-1; *P<0.05,
#P<0.10.
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Figure 12: Actin and MyoD are significantly up-regulated after Atp10c-silencing in
C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes, then transfected at each
concentration of siRNA (SI00906220) (0 nM and 50 nM) and collected at the designated
time point (24 hours). Proteins were collected from these samples and subjected to
immunoblot analysis. Data shown is representative of multiple independent experiments
(n=2 to 4), all analyzed in triplicate. The expression of MyoD and Actin is denoted as
arbitrary units (A.U.) and represented as the fold change normalized to Caveolin-1;
*P<0.05.
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Figure 13: GLUT1 is significantly up-regulated in Atp10c-silencing C2C12 myotubes
C2C12 cells were seeded onto chamber slides and allowed to differentiate from
myoblasts to myotubes. Myotubes were then transfected at each concentration of siRNA
(SI00906220) (0 and 50 nM) and fixed at the designated time point (24 h). After
transfections, cells underwent standard immunofluorescence processing and were
imaged. Each sample was compared to negative and positive controls, which were used
to quantify the image results. The expression of GLUT1 and GLUT4 is denoted as
arbitrary units (A.U.) and represented as the mean intensity fluorescence normalized to
isotype controls; *P < 0.05.
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Moreover, results from our in vivo data are complementary to our in vitro data as we see
a significant up-regulation in the same MAPK proteins (Figure 14A-C) after 12 weeks on
a high fat diet. Namely, MAPK proteins, p38 (P = 0.02) and phospho-p38 (P = 0.001)
and well as ERK1/2 (P = 0.02 and 0.00004, respectively) and phospho-ERK1/2 (P = 0.02
and 0.01 respectively) are significantly up-regulated in Atp10c heterozygous mutants. For
these samples, unlike in vitro conditions, we also observe an up-regulation of JNK (P =
0.00007) and phospho-JNK (P = 0.0001). Reasons for this aberration could be that the
chronic stress conditions of DIO, T2D, hyperinsulinemia, hypercholesterolemia, and
NAFLD as seen in these mice, result in a higher level of the stress-activated JNK and
phospho-JNK proteins. Moreover, multiple studies show that obesity and T2D are
inflammatory diseases, a state which in of its self is stressful on the tissues. This stress is
not observed in vitro as the cells do not have to compensate for whole body
abnormalities.
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Figure 14A: MAPK proteins, p38 and phospho-p38 are significantly up-regulated in
Atp10c heterozygous mutants at 12 weeks on a high fat diet
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 and 12 weeks, and
then sacrificed. Proteins were collected from the skeletal muscle of these mice and
subjected to immunoblot analysis. Data shown are representative of multiple
independent experiments (n = 2 to 4), all analyzed in triplicate. The expression of p38
and phospho-p38 is denoted as arbitrary units (A.U.) and represented as the fold change
normalized to Caveolin-1; *P<0.05.
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Figure 14B: MAPK proteins, ERK1/2 and phospho-ERK1/2 are significantly upregulated in Atp10c heterozygous mutants at 12 weeks on a high fat diet
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 and 12 weeks, and
then sacrificed. Proteins were collected from the skeletal muscle of these mice and
subjected to immunoblot analysis. Data shown are representative of multiple
independent experiments (n = 2 to 4), all analyzed in triplicate. The expression of
ERK1/2 and phospho-ERK1/2 is denoted as arbitrary units (A.U.) and represented as the
fold change normalized to Caveolin-1; *P<0.05.
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Figure 14C: MAPK proteins, JNK and phospho-JNK are significantly up-regulated
in Atp10c heterozygous mutants at 12 weeks on a high fat diet
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 and 12 weeks, and
then sacrificed. Proteins were collected from the skeletal muscle from these mice and
subjected to immunoblot analysis. Data shown are representative of multiple
independent experiments (n = 2 to 4), all analyzed in triplicate. The expression of JNK
and phospho-JNK is denoted as arbitrary units (A.U.) and represented as the fold change
normalized to Caveolin-1; *P<0.05.
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Figure 14D: MyoD is significantly altered in Atp10c heterozygous mutants at 12
weeks on a high fat diet
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 and 12 weeks, and
then sacrificed. Proteins were collected from these mice and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of MyoD is denoted as arbitrary units (A.U.)
and represented as the fold change normalized to Caveolin-1; *P<0.05.
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Under acute insulin-stimulated glucose uptake conditions in C210c/- cells, results
indicated significant up-regulation of p38 (P = 0.02) and a significant down-regulation of
phospho-38 (P = 0.01), JNK (P = 0.0003), and phospho-ERK1/2 (P = 0.015 and P =
0.017 respectively) (Figure 15A-C). It is our hypothesis based on the in vivo results of
the MAPK proteins is that the Atp10c-mutants on a high-fat diet for 4 weeks give us a
better representation of what would be going on in a pre-diabetic state before chronic IR
and T2D has manifested. As such, this time point is better suited to compare with our in
vitro data, as Atp10c-silenced cells would better represent an acute state of IR rather than
a chronic one. As such, all the results from these experiments were performed with
samples obtained from 4 week old mice on a high-fat diet. As such, results from our in
vivo data are somewhat confusing when compared to our in vitro data. Complementary
to our in vitro data, there is an up-regulation of p38 and ERK1/2, but not of significance
(Figure 16A-C). The results are contradictory to our in vitro data in that there is upregulation in phospho-p38 (P = 0.005), phospho-ERK2 (P = 0.03), JNK (P = 0.1) and
phospho-JNK (P = 0.007). Reasons for these discrepancies could be as follows: (1) a
time point of 4 weeks was not long enough to see marked changes in any of the proteins
as the observed changes even when significant are small, (2) the insulin dose was not
enough for the animals and therefore either a larger dose should be used, (3) a shorter
treatment time (less than 30 min) for the insulin challenge should be used, (4) based on
the standard error for these results, there is great variability between from animal to
animal in response to an insulin challenge and/or (5) the fat from the high-fat diet did not
contribute a substantial amount of calories to induce greater DIO consequences. This
point can be corrected with greater numbers of mice. Future work using skeletal muscle
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collected from these Atp10c-mutant mice after 12 weeks on high-fat diet needs to be
performed in order to elucidate a more precise mechanism of action of Atp10c in vivo.
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Figure 15A: MAPK proteins, p38 and phospho-38 are significantly altered after
Atp10c-silencing and acute insulin stimulation in C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes. Myotubes were transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM), stimulated with insulin (100 nM,
30 min) and collected at the designated time point (24 h). Proteins were collected from
these samples and subjected to immunoblot analysis. Data shown are representative of
multiple independent experiments (n = 2 to 4), all analyzed in triplicate. The expression
of p38 and phospho-p38 is denoted as arbitrary units (A.U.) and represented as the fold
change normalized to Caveolin-1; *P<0.05.
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Figure 15B: A MAPK protein, phospho-ERK1/2, is significantly down-regulated
after Atp10c-silencing and acute insulin stimulation in C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes. Myotubes were transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM), stimulated with insulin (100 nM,
30 min) and collected at the designated time point (24 h). Proteins were collected from
these samples and subjected to immunoblot analysis. Data shown are representative of
multiple independent experiments (n = 2 to 4), all analyzed in triplicate. The expression
of ERK1/2 and phospho-ERK1/2 is denoted as arbitrary units (A.U.) and represented as
the fold change normalized to Caveolin-1; *P<0.05.
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Figure 15C: A MAPK protein, JNK, is significantly down-regulated after Atp10csilencing and acute insulin stimulation in C2C12 myotubes
C2C12 myoblasts were differentiated into myotubes. Myotubes were transfected at each
concentration of siRNA (SI00906220) (0 and 50 nM), stimulated with insulin (100 nM,
30 min) and collected at the designated time point (24 h). Proteins were collected from
these samples and subjected to immunoblot analysis. Data shown are representative of
multiple independent experiments (n = 2 to 4), all analyzed in triplicate. The expression
of JNK and phospho-JNK is denoted as arbitrary units (A.U.) and represented as the fold
change normalized to Caveolin-1; *P<0.05.
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Figure 16A: A MAPK protein, phospho-p38, is significantly up-regulated after acute
insulin stimulation in Atp10c heterozygous mutants
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 weeks, and then
sacrificed. Proteins were collected from these mice and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of p38 and phospho-p38 is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to Caveolin-1; *P<0.05.
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Figure 16B: A MAPK protein, phospho-ERK2, is significantly up-regulated after
acute insulin stimulation in Atp10c heterozygous mutants
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 weeks, and then
sacrificed. Proteins were collected from these mice and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of ERK1/2 and phospho-ERK1/2 is denoted as
arbitrary units (A.U.) and represented as the fold change normalized to Caveolin-1;
*P<0.05.
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Figure 16C: A MAPK protein, phospho-JNK, is significantly up-regulated after
acute insulin stimulation in Atp10c heterozygous mutants
Atp10c heterozygous mice (n = 6 to 8) were fed a high-fat diet for 4 weeks, and then
sacrificed. Proteins were collected from these mice and subjected to immunoblot
analysis. Data shown are representative of multiple independent experiments (n = 2 to 4),
all analyzed in triplicate. The expression of JNK and phospho-JNK is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to Caveolin-1; *P<0.05.
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Since the PI3K/Akt pathway has been shown to be the most important pathway
for insulin-stimulated glucose uptake and therefore, GLUT4 translocation, we used the
rat L6-G4myc cells to examine both the PI3K pathway and its association with the
translocation of GLUT4. For PI3K proteins, results indicated a significant decrease in
PI3K at 48 h-post transfection (P = 0.02) (Figure 17A). Results from this analysis also
show a significant down-regulation of Akt2 (P = 0.03) and phospho-Akt (Ser473) (P =
0.01) (Figure 17B). AS160 (P = 0.008), IR-β (P = 0.02), and IRS-2 (P = 0.004) are all
up-regulated significantly 48 h post-Atp10c silencing (Figures 17A-B). While not
significant, there was also an observed up-regulation of Actin (P = 0.1). Moreover, the
expression of GLUT4 appears to be up-regulated in these cells (P = 0.01), but we
attribute this increase due to the GLUT4 overexpressing nature of the L6-G4myc cells
and not as a direct effect of Atp10c-silencing on these cells. Moreover, this result
suggests that protein transcription and translation of GLUT4 are not being effected due to
Atp10c-silencing and therefore, not a cause of the observed IR and T2D. Starting at the
level of the IR-β, we observed an up-regulation here and downstream at IRS-2, and then a
down regulation of phosphotyrosine associated PI3K activity, and Akt and its
phosphorylation at Ser473. The usual pattern observed is that the acute effect of insulin
will down regulate all these proteins [9]. As demonstrated by our results, Atp10c may
play a role in the activation of these proteins further downstream in the pathway, a
portion of which is still largely unknown. Moreover, the activation of Akt at Ser473 in
response to insulin provides potential explanations for many abnormalities including IR.
While it is known that Akt activation requires phosphorylation at both Ser473 and
Thr308, Ser473 phosphorylation was shown to precede the phosphorylation of Thr308
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and is in fact a prerequisite for Thr308 phosphorylation [1]. This can help explain why
we see an up-regulation downstream at AS160 as it is not fully activated and thus is
trying to compensate for the inactivity of Akt.
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Figure 17A: PI3K, IR-β, and IRS-2 are significantly altered after Atp10c-silencing
and acute insulin stimulation in L6-G4myc myotubes
L6-G4myc myoblasts were differentiated into myotubes. Myotubes were transfected at
each concentration of siRNA (SI00906220) (0 and 50 nM), stimulated with insulin (100
nM, 30 min) and collected at designated time point (48 h). Proteins were collected from
these samples and subjected to immunoblot analysis. Data shown are representative of
multiple independent experiments (n = 2 to 4), all analyzed in triplicate (*P < 0.05). The
expression of PI3K, IRS-2, and IR-β is denoted as arbitrary units (A.U.) and represented
as the fold change normalized to Caveolin-1.
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Figure 17B: PI3K proteins, Akt2, phospho-Akt, and AS160 are significantly altered
after Atp10c-silencing and acute insulin stimulation in L6-G4myc myotubes
L6-G4myc myoblasts were differentiated into myotubes. Myotubes were transfected at
each concentration of siRNA (SI00906220) (0 and 50 nM), stimulated with insulin (100
nM, 30 min) and collected at designated time point (48 h). Proteins were collected from
these samples and subjected to immunoblot analysis. Data shown are representative of
multiple independent experiments (n = 2 to 4), all analyzed in triplicate (*P < 0.05). The
expression of Akt2, phospho-Akt, and AS160 is denoted as arbitrary units (A.U.) and
represented as the fold change normalized to Caveolin-1.
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Figure 17C: Actin and GLUT4 are significantly up-regulated after Atp10c-silencing
and acute insulin stimulation in L6-G4myc myotubes
L6-G4myc myoblasts were differentiated into myotubes. Myotubes were transfected at
each concentration of siRNA (SI00906220) (0 and 50 nM), stimulated with insulin (100
nM, 30 min) and collected at designated time point (48 h). Proteins were collected from
these samples and subjected to immunoblot analysis. Data shown are representative of
multiple independent experiments (n = 2 to 4), all analyzed in triplicate (*P < 0.05). The
expression of Actin and GLUT4 is denoted as arbitrary units (A.U.) and represented as
the fold change normalized to Caveolin-1.
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In vivo data from Atp10c heterozygous mice fed a high-fat diet for 4 weeks show
that several key PI3K pathway proteins are altered when challenged with insulin (Figure
18A-B). While not significant, there was an observed up-regulation of Actin (P = 0.2),
which correlates to our in vitro experiment. However, PI3K (P = 0.003), Akt2 (P =
0.006), phospho-Akt (Ser473) (P = 0.02), and AS160 (P = 0.01) are all up-regulated
significantly in vivo, data again which both complements and conflicts with our in vitro
data. Data for IR-β, and IRS-2 was inconclusive for these samples due to antibody
issues, and therefore, were not reported. Again, several reasons for these discrepancies
exist (variation between animals, inefficient insulin dose, etc.) and future experiments
should look at addressing those. Having said that, the up-regulation and activation of
these proteins makes sense as this pathway is responsible the majority of glucose uptake
in insulin responsive tissues. While a previous reports [87, 88, 89]have shown that highfat feeding impairs insulin signal transduction by affecting tyrosine phosphorylation of
insulin receptors and their substrates, results from other studies have shown that insulininduced tyrosine phosphorylation of insulin receptors and their substrates is similar
between animals fed a high-fat diet and those on a regular chow diet [1]. Recently, it was
demonstrated that despite the development of IR, which is accompanied by reduced
glucose-uptake rates in muscle cells, no changes in the phosphorylation state of Akt and
AS160 were observed [4]. Our results contradict both of these observations as we seen a
significant up-regulation of many important components of the PI3K and yet these
animals still have issues with glucose metabolism. This suggests that something other
than a defect in the PI3K pathway is causing the observed phenotype in these Atp10c
heterozygous mice.
103

Caveolin-1

PI3K

Akt2

AS160

phospho-Akt2

*

*
*

*

A.

Figure 18A: PI3K proteins, PI3K, Akt2, phospho-Akt2, and AS160 are significantly
up-regulated in Atp10c-heterzygous mutants after acute insulin-stimulation
Atp10c heterozygous mice were fed a high-fat diet for 4 weeks, and then sacrificed.
Proteins were collected from these mice and subjected to immunoblot analysis. Data
shown are representative of multiple independent experiments (n = 2 to 4), all analyzed in
triplicate (*P < 0.05). The expression of PI3K, Akt2, phospho-Akt, and AS160 is denoted
as arbitrary units (A.U.) and represented as the fold change normalized to Caveolin-1.
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Figure 18B: MyoD is significantly altered Atp10c-heterzygous mutants after acute
insulin-stimulation
Atp10c heterozygous mice were fed a high-fat diet for 4 weeks, and then sacrificed.
Proteins were collected from these mice and subjected to immunoblot analysis. Data
shown are representative of multiple independent experiments (n = 2 to 4), all analyzed in
triplicate (*P < 0.05). The expression of Actin and MyoD is denoted as arbitrary units
(A.U.) and represented as the fold change normalized to Caveolin-1.

105

GLUT4 is essential for insulin-stimulated glucose uptake, and is expressed
primarily in adipose and skeletal muscle tissues. Ideally, in response to insulin,
intracellular GLUT4 vesicles move near the cell surface, fuse with the plasma membrane,
and begin the process of glucose uptake. Defective uptake of glucose is a central feature
of T2D, and may involve the alteration of the insulin signaling to GLUT4 vesicles, the
trafficking of GLUT4 vesicles to the plasma membrane, and/or the docking and fusion of
GLUT4 vesicles with the plasma membrane. As we did see a significant decrease in
glucose uptake (2.5 fold), and a significant increase in GLUT4 expression (P = 0.01), we
next wanted to investigate the effect, if any, on GLUT4 translocation when Atp10c is
silenced in L6-G4myc myotubes. The data from immunocytochemistry experiments
shows a decrease in insulin-stimulated GLUT4 translocation to the plasma membrane
after 48 h post-transfection in L6-G4myc/10c- myotubes (Figure 19), and as such, a
decrease in insulin-stimulation of these cells.
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Figure 19: GLUT4 translocation in Atp10c-silenced L6-G4myc myotubes is
decreased 48 h post-transfection
L6-G4myc myotubes were transfected at each concentration of siRNA (SI00906220)
(0nM and 50 nM) at the designated time point (48 h). Cells were then stimulated with
insulin (100 nM), and an immunocytochemistry assay was performed (*P < 0.05). Data
is reported as GLUT4 translocation which is expressed as the ratio of GLUT4myc
intensity under basal and stimulated conditions and indicated as arbitrary units (A.U.).
Data is normalized with respect to 0nM basal and stimulated controls.
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To test if the observed changes in the MAPK pathway are indeed in response to
Atp10c-silencing, and thus to confirm the involvement of p38, the inhibitor SB203580,
which is specific for multiple p38 isoforms, was added to C210c/- cells at a concentration
of 10 μm for 60 min [90, 91]. Protein samples were subjected to immunoblot analysis
with p38 and phospho-p38 antibodies (Figure 20). Our results indicate that C210c/- cells
treated with 10 nM SB203580 for 60 min effected the expression of both p38 (P = 0.1)
and phospho-p38 (P = 0.08). While not significant, it appears that the inhibitor was able
to partially restore the expression of all the proteins tested suggesting its action on the
MAPK protein, p38. This was further confirmed by the glucose uptake assay performed
on C210c/- and MAPK-inhibited cells. Results from the assay showed that glucose
uptake remained unchanged, confirming that the inhibitors are acting directly on the
MAPK protein, p38, and are not affected by changes in Atp10c expression alone (Figure
21).
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Figure 20: MAPK protein, p38, activity is partially rescued after treatment with
specific inhibitor SB203580
C2C12 cells were differentiated from myoblasts to myotubes. Myotubes were transfected
at each concentration of siRNA (SI00906220) (0 and 50 nM) at the designated time point
(24 h). Cells were then treated with the inhibitor SB203580 (10 nM) and collected after
60 min. Proteins were collected from these samples and subjected to immunoblot analysis
(*P < 0.05, #P < 0.1). The expression of p38 and phospho-p38 is denoted as arbitrary
units (A.U.) and represented as the fold change normalized to Caveolin-1.
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Figure 21: Glucose uptake remained unchanged, confirming that the p38 inhibitors
are acting directly on the MAPK proteins and are not affected by changes in Atp10c
expression
C2C12 cells were differentiated from myoblasts to myotubes. Myotubes were treated
with the inhibitor SB203580 (10 nM) and collected after 60 min. Cells were then
stimulated with insulin (100 nM, 30 min) and a 2-DOG uptake was performed. Data is
reported as the glucose uptake stimulation which is expressed as the ratio of dpm/µg of
total protein in presence of insulin to that in the absence of insulin and indicated as
arbitrary units (A.U.).
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The exact mechanism by which the MAPKs mediate glucose uptake is debatable,
and as such that both in vitro and in vivo data are often times inconclusive. MAPKs,
specifically, p38 and ERK1/2 proteins regulate glucose uptake via insulin-dependent and
insulin-independent pathways [87, 88, 89]. Most importantly, there are many reports
which show the involvement of the MAPK pathway in glucose uptake without an effect
on GLUT4 translocation. Our results suggest that when myotubes become insulin
resistant by Atp10c-silencing, there is a significant increase in the expression of both
native and activated (phosphorylated) MAPK proteins. Data demonstrates that both p38
and ERK1/2 are responsive to changes in Atp10c with increased expression.
The importance of p38 in this process is further supported by the fact that there
are significant changes in glucose transporter proteins as well. GLUT1 and GLUT4 have
been demonstrated to be the key players of glucose clearance in peripheral tissues [2].
GLUT1 is responsible for glucose uptake in the basal state whereas, GLUT4 is insulin
responsive. Defective uptake of glucose mediated by the GLUTs is a central feature of
DIO and T2D.
Results from our in vivo analysis of Atp10c heterozygous mice demonstrate that at
the protein level, the expression of key MAPK proteins are up-regulated during an IR
state and remain up-regulated when challenged with exogenous insulin. As a
consequence of IR, there is a shift away from GLUT4 as the main player in glucose
clearance to GLUT1 as the responsible transporter. Results from several studies in
addition to ours show that prolonged exposure to insulin increases basal glucose uptake
and decreases acute insulin-mediated glucose transport. The latter attributed to reduced
insulin-stimulated GLUT4 translocation. However, it is still possible that the insulin111

resistant state is associated with diminished GLUT4 activity as our in vitro data shows a
significant increase in GLUT1 and no measurable change in GLUT4. Of relevance to our
study, MAPK protein expression, specifically p38, has been shown to affect the
expression of GLUT1 and GLUT4; which can subsequently affect glucose uptake in
peripheral tissues. The MAPK protein, p38, reportedly up-regulates the expression of
GLUT1, thereby altering glucose transport at the basal level, while also involved in an
insulin-induced enhancement of intrinsic GLUT4 activity on the cell surface. Since, we
do not see any increase in the basal glucose uptake, we strongly feel that the upregulation of GLUT1 is more of a compensatory mechanism against IR in C210c/-, since
there is no change in GLUT4; the precise underlying mechanism, however, remains to be
clarified. This result may prove to be the most crucial, as GLUT4 is the main player in
insulin-stimulated glucose metabolism. Reports additionally indicate that the activation of
p38 reduces insulin responsiveness [87, 88, 89, 90], so the exact mechanism by which the
MAPK pathway is involved in glucose metabolism still remains controversial.
Up-regulation of MyoD and Actin in transfected cells (C210c/-) suggests a
regulatory mechanism by which the myotubes are trying to combat the stressful state of
IR. As seen in the skeletal muscle tissues of the Atp10c mutant mice fed a high-fat diet
for 12 weeks, MyoD expression is decreasing as a result of the insulin resist state and a
high fat diet; this observation was not seen for these mice at 4 weeks on a high-fat diet..
As the availability of new myoblasts cells in vivo is not the same as in vitro, this result is
indicative of muscle wasting and/or myotube de-differentiation. Again, this may be a
compensatory effect. If the in vitro process continued for a longer period of time, we
hypothesis that like the tissues, the expression of MyoD would also decreases as the
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myotubes started reverting back to a myoblast state. By aiding with GLUT4-containing
vesicle membrane movement and/or fusion, there is considerable evidence that Actin is
essential for insulin-regulated glucose transport. Therefore, these cells may be upregulating the expression of Actin acutely in preparation for insulin-stimulated glucose
uptake [76].
Multiple studies on skeletal muscle from type 2 diabetics have demonstrated an
altered gene/protein expression profile compared to healthy controls [71]. These changes
can either be secondary to the altered metabolic state, a direct consequence of reduced
insulin signaling, or as the primary cause of the disease. The defects observed in diabetic
muscle biopsies were reportedly specific for the PI3K pathway, thereby leaving the
MAPK pathway intact. However, unlike our study, other laboratories discovered that
several of the MAPK proteins were down-regulated at the protein expression level.

Conclusions
A phenomenon known as phospholipid randomization affects the structure and
function of many channels, transporters, and signal transducing proteins and has been
implicated in several pathophysiology processes. Thus, maintaining the organization and
activity of the lipid bilayer is essential for normal cell function. One class of proteins that
performs this action is the flippases, or type 4 ATPases [7]. In yeast studies, these
proteins cause the translocation of glycerophospholipids, and this movement is necessary
for intracellular membrane and protein trafficking [7]. Atp10c is one such phospholipid
translocase which encodes for a type 4 P-type ATPase. Our laboratory has demonstrated
that Atp10c heterozygous mice are insulin resistant and have an altered insulin-stimulated
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response in peripheral tissues. Our obesity mouse model is diet-induced and shows IR
characterized by hyperinsulinemia, hyperglycemia, hyperlipidemia, and DIO in
association with glucose intolerance [2, 36, 72]. In fact, a recent publication has sited
ATP10C as a potential biomarker for obesity and related metabolic disorders [12].
The pathways involved in glucose and lipid metabolism are extremely complex
and challenging to interpret. Atp10c is a proposed membrane bound protein with 10-11
transmembrane domains and its flippase activity has been studied extensively in yeasts.
This is why we hypothesize one or more mechanisms of action on the membrane itself
which can in turn affect these pathways. The activation of the PI3K pathway and its
downstream kinases like Akt include the GLUT4 translocation. This insulin-dependent
pathway is the one of the most important in glucose metabolism, accounting for up to
70% of glucose clearance. Numerous studies have shown Akt and its related substrates to
be the key players in this pathway. Importantly, Akt, which regulates GLUT4
exocytosis, is not required for insulin regulation of GLUT4 endocytosis [92].
The significant increase of important MAPK proteins, p38 and ERK1/2, under
both basal and acute insulin-stimulated conditions shows that Atp10c-silencing does
affect these proteins and in turn, glucose metabolism via both insulin-independent and
insulin-dependent manners. Results from the PI3K pathway proteins are confusing as in
vitro data does not complement the in vivo data for all the proteins. For example, PI3K (P
= 0.02), Akt2 (P = 0.03) and phospho-Akt (Ser 473) (P = 0.01) are significantly downregulated after Atp10c silencing under in vitro conditions, but are significantly upregulated in the Atp10c-heterozygous mice on a high-fat diet; PI3K (P = 0.003), Akt2 (P
= 0.006) and phospho-Akt (Ser 473) (P = 0.02). Rationale for these conflicting results
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could be that Atp10c could be involved with these proteins directly by a yet unknown
mechanism, or as a consequence of Atp10c’s effect on the MAPK pathway which is
significantly affected by the diet as indicated in the mice. These results are important as
the activation of Akt2 plays a critical role in the PI3K pathway by further activating
AS160 (phospho-Akt Ser473/Thr308). It is important to note that only 10–20% of Akt2
needs to be phosphorylated to achieve full glucose transport activation [47, 48]. IRS-2
plays a key role in transmitting signals to both intracellular pathways PI3K and MAPK. It
appears as though the cells are trying to augment signaling to these pathways to
compensate for inactivity (as in PI3K) or over activity (as in MAPK) in these pathways.
In the case of the PI3K pathway, Atp10c appears to be halting the activation of PI3K
(p85) and phospho-Akt2. As a result, we see up-regulation both up stream in IR-β and
IRS2 and downstream in AS160. In turn, IRS-2 may be sending these compensatory
signals to MAPK proteins [72]. As such, the up-regulation of p38 must be in response to
shift the uptake from GLUT4 as the main player to GLUT1 as the main player as p38 has
been directly implicated in the regulation of these glucose transporters. Activation of p38
significantly alters the expression of GLUT1 and GLUT4, increasing basal glucose
transport and reducing insulin responsiveness [91]. As p38 up-regulation resulted in an
increase in GLUT1 and an assumed decrease in GLUT4, it is highly likely that p38 is
central in the regulation of glucose metabolism. Moreover, in data from others [41, 90,
91] as well as our laboratory, the pyridinylimidazole inhibitor of p38 activity, SB203580,
reduced the stimulation of glucose uptake by insulin in skeletal muscle suggesting that
p38 may be a component in the signaling pathway leading to the stimulation of glucose
uptake.
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Results from the immunocytochemistry analysis of GLUT4 translocation show
that the silencing of Atp10c is altering normal GLUT4 regulation. At this time, it appears
as though Atp10c most likely plays a role in GLUT4 endocytosis. Although GLUT4
exocytosis has been studied extensively, GLUT4 endocytosis and its possible regulation
had remained less scrutinized. Recent studies have begun to shed light on GLUT4
endocytic mechanisms and their metabolic regulation [92]. Endocytosis involves GLUT4
molecules getting ‘ready’ by concentrating within a small region of the plasma
membrane. Secondly, they get ‘set’ by interacting with specific membrane proteins
and/or lipids, resulting in membrane bending and invagination. Finally, the bud is formed
occluding GLUT4 from the extracellular milieu and allowing them to ‘go’ into the cell
interior to intracellular compartments. It has been reported that the internalization of
GLUT4 occurs by clathrin-mediated endocytosis [42]. Moreover, it has been argued that
GSVs are formed from endosomes and that GLUT4 may be retained intracellular by an
interaction between GSVs and retention machinery, or by restricting the access of GSVs
to the vesicle tethering/docking/fusion apparatus at the cell surface [40, 42]. Based on
our results, it is possible that ATP10C is involved in either of these steps in addition to its
other effects on the metabolic pathways.
Addressing the discrepancies between in vivo and in vitro data is difficult at best
as we are dealing whole animal complexities compared to cell culture homogeneity.
Moreover, these metabolic pathways themselves are multifaceted in whole animal models
due to the interplay of endogenous cytokines, apidokines and other nature responses in
response to chronic syndromes like IR and T2D. We feel confident that our results for the
most part are complementary to one another with only two major points of conflict—the
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expression of PI3K, Akt2 and phospho-Akt (Ser473). These observations demonstrate the
necessity of a muscle-specific Atp10c knockout to study these complex processes.
For the first time, our results show a direct correlation between Atp10c/ATP10C
and glucose metabolism, at least in part via the MAPK pathway. Our results showed no
significant change in the basal glucose uptake suggesting that when Atp10c is silenced
using Atp10c-specific siRNA an acute state of IR is observed. Conversely, cells are
insulin sensitive when normal levels of Atp10c are maintained; both observation shown in
vitro as well as in vivo. The MAPK protein, specifically p38, is potentially influencing
this system by exerting an effect on glucose transporter proteins, namely GLUT1 and
GLUT4. Moreover, we showed that the MAPK pathway is essential for both insulinindependent and insulin-dependent glucose uptake; exact mechanisms of which need
further study. Last, but certainly not least, we have revealed Atp10c’s possible role in
GLUT4 endocytosis in addition to its other effects on the glucose metabolic pathway.
Based on the results of the numerous studies discussed throughout this dissertation,
Figure 22 presents putative Atp10c/ATP10C mechanisms of action and possible
protein/pathway targets.
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Figure 22: Atp10c/ATP10C in Action
ATP10C may function by activating key proteins in the PI3K pathway and
influence glucose uptake in connection with GLUT4 translocation (1). Moreover, it may
exert its affects downstream thus affecting glucose uptake that way (2). When normal
expression levels of ATP10C are maintained, MAPK proteins should not be up-regulated
and therefore normal glucose uptake both at the basal and insulin-stimulated level should
occur (3) and last, but not least, ATP10C may function on the endocytosis as well as the
exocytosis of GLUT4 by several machineries; (4) by maintaining lipid bilayer asymmetry
and cell homeostasis, (5) as an aid in GSV formation, (6) by retaining the GSVs inside
the cell, and (7) by stimulating the endocytosis of GLUT4 back inside the cell.
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CHAPTER IV
OVERALL CONCLUSIONS AND FUTURE RECOMMENDATIONS
The prevalence of T2D and DIO has reached epidemic levels during recent years
and shows no progress of slowing down. Moreover, it is estimated that less than half of
the worldwide patient population responds to existing treatments, and as such increases
the occurrence of secondary complications of the disease. The currently accessible
treatments offer improvement in glycemic control, but have also been implicated with
significant adverse events such as hypoglycemia, weight gain, fluid retention, congestive
heart failure, loss of bone mineral density and gastrointestinal discomfort. Our research
eludes to a novel protein marker that we believe is a good candidate for T2D and DIO
and therefore, it’s modification may play a role in expanding the treatment of T2D and
other diseases associated with IR, findings of which are significant as many of the antidiabetic drugs currently on the market have undesirable side-effects like those previously
described.
Glucose metabolism is reduced in type 2 diabetics resulting in elevated levels of
glucose in the bloodstream, and complications of IR and T2D can be either short term
(e.g. diabetic coma) or long term (e.g. limb amputation, neuropathies, kidney failure,
strokes, and other cardiovascular problems). As glucose is vitally important for animals
and humans, its concentration in the blood is strictly controlled. Glucose homeostasis in
the body is the responsibility of key peripheral tissues, skeletal muscle and adipose tissue,
and glucose utilization is carried out by GLUTs specifically GLUT4. GLUT4 trafficking
is constitutive, highly regulated, multi-compartmental and involves multiple proteins. As
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this protein is the most important player in glucose homeostasis, it is feasible that defects
at any of the several activation steps could alter trafficking and targeting of GLUT4.
Therefore, it is critically important to elucidate the molecular mechanisms leading to
GLUT4 function and how any alteration impairs translocation in response to insulin.
These defects would have important implication for both treatment and prevention of
T2D and other related metabolic disorders.
Atp10c/ATP10C is a putative phospholipid translocase that plays a role in the
maintenance of the phospholipid asymmetry and fluidity of the plasma membrane. In
view of this property of Atp10c/ATP10C, and the displayed phenotype in the
heterozygous mice, a loss of Atp10c/ATP10C function might upset the normal membrane
environment, and as such, perturbs glucose metabolism. Inclusion of all the studies
discussed in this dissertation, we established the legitimacy of our gene as a good
candidate for DIO and T2D, potentially via the disruption of glucose metabolism. In
view of the data presented here and the literature discussed, we are encouraged in using
this model to dissect metabolic pathways involved in glucose and lipid metabolism thus
gaining a better understanding of the underlying molecular mechanisms. Additionally,
we validated Atp10c’s possible biological function by showing its location at or around
the plasma membrane, and its suggested co-localization with GLUT4 (81%).
Furthermore, we validated by Atp10c’s increased expression in two mice models of
obesity, one a genetic model and the other an environmental one.
As glucose and lipid metabolism pathways are of great importance, we have
focused on two pathways, the PI3K and the MAPK. Utilizing siRNA technology to alter
the expression of Atp10c in vitro, our laboratory measured key pathway protein
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expression by both Western blot and immunofluorescence techniques. Results of both in
vitro as well as in vivo studies demonstrated a key role for MAPK proteins, specifically
p38, in both insulin-independent, but also insulin-dependent glucose clearance.
Moreover, information gleamed from these studies show a possible mechanism by which
p38 and therefore, the MAPK pathway, work in mediating glucose metabolism and thus
influences IR and T2D. Function assays of 2-DOG glucose uptake and
immunocytochemistry of GLUT4 translocation were also performed, results of which
revealed significant decreases in acute insulin stimulated glucose uptake and GLUT
translocation. We believe that the resulting decrease in translocation is the direct
consequence of Atp10c’s role in the endocytosis of GLUT4 and not an effect on the
MAPK pathway, an answer which is not surprising given the literature on MAPKs noninvolvement in GLUT4 translocation. Thus, in vitro functional outcomes again mimicked
in vivo ones. However, we believe future work to confirm this result needs to be
performed using L6-G4myc myotubes treated with p38-specific inhibitors, and repeat the
translocation of GLUT4 to see if any changes are observed. For the future of this work,
from an in vitro standpoint, stable cell lines, either over-expressing ATP10C or with
ATP10C deleted should be generated and the above mentioned experiment repeated.
From an in vivo perspective, specific targeted experiments to generate adipose tissue and
skeletal muscle-specific transgenics are necessary. Then, the assessment of protein
expression of these target genes should be initiated. Tissue-specific expression of Atp10c
transgenes will determine if Atp10c expressed solely in muscle or in adipocytes will
complement the mutant phenotypes. These experiments will give us information about
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defects associated with the heterozygous deletion of Atp10c in a target tissue without any
interference from its expression/miss-expression in the other.
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